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Abstract
The field of Cannabis sativa L. research for medical purposes has been rapidly advancing in recent decades and a growing 
body of evidence suggests that phytocannabinoids are beneficial for a range of conditions. At the same time impressing 
development has been observed for formulations and delivery systems expanding the potential use of cannabinoids as an 
effective medical therapy. The objective of this review is to present the most recent results from pharmaceutical companies 
and research groups investigating methods to improve cannabinoid bioavailability and to clearly establish its therapeutic 
efficacy, dose ranges, safety and also improve the patient compliance. Particular focus is the application of cannabinoids in 
pain treatment, describing the principal cannabinoids employed, the most promising delivery systems for each administration 
routes and updating the clinical evaluations. To offer the reader a wider view, this review discusses the formulation starting 
from galenic preparation up to nanotechnology approaches, showing advantages, limits, requirements needed. Furthermore, 
the most recent clinical data and meta-analysis for cannabinoids used in different pain management are summarized, evaluat-
ing their real effectiveness, in order also to spare opioids and improve patients’ quality of life. Promising evidence for pain 
treatments and for other important pathologies are also reviewed as likely future directions for cannabinoids formulations.
Key Points 
Beneficial effects of cannabinoids formulations have 
been proved in clinical studies for several diseases.
Explore different administration routes to improve can-
nabinoid efficacy.
Efforts have been made to reduce pain and to improve 
quality of life of patients by designing appropriate for-
mulations of cannabinoids.
1 Introduction
Although cannabinoids have attracted attention for centu-
ries, the last few decades have brought new and scientifically 
well-founded insights into their therapeutic potential. The 
use of Cannabis sativa L. for medical purposes, including 
herbal cannabis products and purified single active agents 
(mainly cannabinoids), has become increasingly available 
to patients in many countries in recent years and contin-
ues to evolve. The official introduction of pharmaceutical-
grade cannabis flowers for medicinal purposes has allowed 
physicians and pharmacists to legally prepare and prescribe 
cannabis-based products. Several countries throughout 
Europe have introduced specific regulations and guidelines 
regarding medicinal cannabis. Analogously, in Canada, the 
cannabis act has improved patient access, while, in the USA, 
the use of cannabis for medical purposes is legal in 36 states.
A growing number of US states now permit its admin-
istration for a plethora of conditions, including chronic and 
cancer-related pain, the nausea and vomiting caused by 
chemotherapy, the spasticity caused by multiple sclerosis 
and paraplegia, sleep disorder, psychosis, Tourette’s syn-
drome, anxiety disorder and glaucoma [1].
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The specific focus of this review is the application of can-
nabinoids in pain treatment, in order to spare opioids and 
other drugs, and their involvement in better patient quality 
of life.
According to the Kyoto protocol of the International 
Association for the Study of Pain, pain has been defined as 
an ‘unpleasant sensory experience associated with actual or 
potential tissue damage or described in terms of such dam-
age’ [2]. Chronic pain, in particular, is a common, complex 
and distressing problem that has a deep impact on individu-
als and society. In the CDC survey in the year 2019, 20.4% 
of US adults had chronic pain and 7.4% of adults had chronic 
pain that frequently limited life or work activities (referred 
to as high-impact chronic pain) [3]. The latest report on the 
Global Burden of Diseases, Injuries and Risk Factors identi-
fied low back pain among the top ten causes for all ages [4]. 
Pain may also be the major symptom in several conditions, 
such as fibromyalgia, endometriosis, inflammatory bowel 
disease, multiple sclerosis, rheumatoid arthritis and cancer. 
Although opioids do have a foundational role in the man-
agement of pain, non-opioid analgesic alternatives should 
be investigated as a means to increase the arsenal available 
to pain physicians. Furthermore, the opioid overdose crisis 
in the USA and the risks and harm that can arise from the 
misuse of medicines for pain management are concerning.
Despite the significant increase in the number of publica-
tions on medical cannabis-related topics, much of the pub-
lished literature and funding for research on cannabis is still 
dedicated to surveys of willing cannabis users and the harm 
that the drug causes [5]. The medical community has been 
reticent to embrace cannabis as a medicine for many reasons, 
including decades of misinformation, poorly designed stud-
ies and lack of quality, standardised products and efficient 
formulations. At the same time, the market was flooded with 
many cannabinoid-based products, and many forms publi-
cised medicinal value that has not been scientifically evalu-
ated. These unregulated products, labelled as cannabinoids, 
may thus be a serious health hazard.
Nevertheless, the vast interest in the subject is clearly 
evident upon an exploration of the increasing number of 
articles and filed patents that evaluate the real efficacy of 
these substances, which were frequently used in the past as 
traditional medicines.
In order to select and suggest the most promising for-
mulations and administration routes for pain treatment, it 
is important to have a wide overview of the cannabinoid 
formulations that have recently been explored and tested 
(years 2018–2021) by industry and research groups. Previ-
ous approaches and data can also be found in our previous 
review [6]. Several formulations have been proposed for 
other therapeutic areas (anorexia, seizure, rare syndromes), 
and knowledge of these is necessary if we are to understand 
their potential effectiveness and limits, and thus their real 
value as potential formulations for pain treatment and to 
improve the patient’s quality of life.
For this reason, we will start by evaluating the galenic 
preparations that include the full spectrum of active ingre-
dients in cannabis inflorescences. The complexity of this 
approach will be discussed as will the interesting, although 
hotly debated, matter of the entourage effect, which 
describes the synergic action of different components in the 
vegetable source.
Then, due to the huge amount of research published and 
patented on cannabinoid applications in recent years, we will 
describe studies that are in advanced clinical evaluations, 
categorised by administration routes, to allow the reader to 
compare the formulation approaches that are being devel-
oped by industry. Furthermore, the more recent development 
of micro- and nano-formulations, which were developed to 
deliver single cannabinoid or complex extracts, will also be 
presented.
Nanoscale designed formulations have been extensively 
studied in recent decades for compounds with high lipophi-
licity, providing significant advantages such as improving 
solubility, optimising their release profiles and increasing 
bioavailability, and have achieved important successes. Con-
sequently, this can lead to the development of convenient 
administration routes, lower toxicity and fewer side effects, 
improved biodistribution and extended drug life cycles [7].
Although only preclinical data are available for the major-
ity of the advanced technologies, some well-established for-
mulations begin to be evaluated in clinical trials.
Tables will be used to summarise the relevant involve-
ment of industries in developing safe and efficient cannab-
inoid-based medicines and, in particular, define the recent 
ongoing clinical tests focused on pain-related treatments.
2  Pain and Role of Cannabinoids
Pain is the result of a series of ample interactions (nervous 
system, metabolic, immunological responses), modulated 
by various factors (environmental, cultural, physical, affec-
tive), that are capable of generating specific characteristics 
for each individual.
Generally, it is possible to identify three different types 
of pain according to the origin of the stimulus: structural 
mechanical nociceptive pain, inflammatory nociceptive pain 
and neuropathic pain (peripheral and central).
Nociceptive pain develops at the peripheral level, follow-
ing the stimulation of nociceptors, which send the stimulus 
through the nerve fibres of the somato-sensory system to 
the spinal cord and then to the thalamus and cerebral cortex. 
Structural mechanical nociceptive pain originates from noci-
ceptors subjected to high intensity stimuli (above the sensi-
bility threshold). Inflammatory nociceptive pain is, instead, 
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caused by a sensitisation of the peripheral nociceptors by the 
mediators of the inflammatory process, which respond, in 
this case, to low intensity stimuli (below threshold) or even 
in the absence of stimuli (spontaneous pain).
Neuropathic pain is the consequence of damage to the 
peripheral nerves (peripheral neuropathic pain) or to the cen-
tral nervous system (central neuropathic pain), which can 
cause the abnormal activity of the genesis of the impulses 
and is characterised by an almost complete lack of correla-
tion between the entity of the peripheral stimulus and the 
painful sensation caused.
Acute pain corresponds to ongoing tissue damage, has a 
limited duration over time and is accompanied by neuroen-
docrine, emotional, and behavioural responses and, if not 
managed correctly, can evolve into chronic pain.
Chronic pain, which by convention lasts more than 3 
months, may no longer have connections with the initial 
cause, so much so that the pain itself becomes a “disease”.
Chronic pain has been linked to numerous physical and 
mental conditions and is one of the most common reasons 
why adults seek medical care. It is also linked to restrictions 
in mobility, daily activities and lost productivity [8]. Chronic 
pain reduces quality of life, causes the onset of anxiety and 
depression and, in some social contexts, dependence on opi-
oids. The estimate of prevalence of chronic pain ranges from 
11 to 40% [9–11].
Nociplastic pain, as defined by the International Asso-
ciation for the Study of the Pain (IASP-PAIN) in 2017, is 
caused by an alteration of nociception, although there is no 
clear evidence of actual or potential tissue damage caus-
ing the activation of peripheral nociceptors or evidence of 
disease or injury to the somatosensory system causing pain. 
This new term replaces other nosological entities such as 
dysfunctional pain or medically unexplained somatic syn-
dromes and groups all the syndromes where chronic primary 
pain is present.
The most common nociplastic pain syndromes are 
chronic widespread pain, fibromyalgia, chronic low back 
pain of unknown causes, chronic visceral pain syndromes 
and others. This type of pain can occur in isolation but in 
these pathologies, pain is often accompanied by other symp-
toms such as fatigue, sleep disturbances, hypersensitivity to 
external stimuli, cognitive impairment and mood disturbance 
[12].
Recognising this type of chronic pain and the underlying 
pathogenetic mechanisms can help define a suitable drug 
treatment such as N-methyl-d-aspartate receptor antagonists 
and cannabinoids aimed at treating the sensitisation of cen-
tral nervous system or peripheral nerve tissues.
There is no doubt about the historic use of plant-derived 
cannabinoids for inflammation and pain relief in many 
cultures since ancient times. While the explanation for 
their anti-inflammatory and analgesic effects remained 
unidentified until the discovery of the endocannabinoid 
system, the rationale for their use now seems to be clearer; 
it is known that the location and signalling of cannabinoid 
receptors are the basis for these effects.
The identification of d-9-tetrahydrocannabinol (THC), 
the compound responsible for the plant’s psychotropic 
effects, paved the way for the discovery of the endocan-
nabinoid system in vertebrates.
Cannabinoid receptors can be viewed in two ways: the 
first “classical” view is that there are only two recognised 
receptors, CB1 and CB2, which are members of the seven 
transmembrane G-protein coupled receptors; while, in a 
more ample view, cannabinoid and endocannabinoid com-
pounds can activate a more widespread range of receptors.
Endogenous cannabinoids are fatty acids with 20 car-
bon atoms (eicosanoids) capable of selectively binding to 
the CB1 and CB2 receptors, the latter is mainly present in 
immune system cells. N-arachidonyl-ethanolamine better 
known as anandamide (AEA) was the first endogenous 
molecule isolated and identified in 1992 in the pig brain, 
followed by the discovery in 1995 of 2-arachidonoylglyc-
erol (2-AG).
Endocannabinoids are synthesised by neurons, fol-
lowing the depolarisation of the membrane and the intra-
cellular increase in calcium levels. The synthesis takes 
place starting from membrane phospholipids, precur-
sors that after enzymatic hydrolysis, by means of two 
enzymes N-acyl phosphatidylethanolamine phospholi-
pase d (NAPE-PLD) and diacylglycerol lipase (DAGL), 
respectively, release the endocannabinoids AEA or 2-AG 
from the pre- or postsynaptic membrane, into the synap-
tic space. They are molecules that have a local effect and 
a short bioavailability as they are rapidly degraded by 
specific enzymes for endocannabinoids (fatty acid amide 
hydrolase, FAAH, and monoacylglycerol lipase, MAGL) 
(Fig. 1).
After release by the postsynaptic neurons, endogenous 
cannabinoids can travel retrograde along the synaptic cleft, 
also binding to presynaptic cannabinoid receptors where 
the CB1 receptors are most prevalent. The activation of 
cannabinoid CB1 receptors involves the inhibition of the 
activity of adenylate cyclase, with less production of the 
second messenger cAMP, initiates the closure of the  Ca2+ 
channels, inhibiting the entry of  Ca2+ ions, and opens the 
potassium channels causing hyperpolarisation of the mem-
branes. Endocannabinoids, that can be defined neuromodu-
lators, through this influence on ion channels, can inhibit 
the release of neurotransmitters from axons, interacting in 
particular with GABA-ergic, serotonergic, glutamatergic, 
and dopaminergic transmissions having an important role 
in some forms of short- and long-term synaptic plasticity. In 
addition, activation of some kinases may also occur, includ-
ing mitogen-activated protein (MAP) kinases (Fig. 1).
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The endocannabinoid system is involved in a large num-
ber of physiological processes, including motor control, 
memory and learning, pain perception, regulation of energy 
balance, and food intake. Other functions of the endocan-
nabinoid system, in normal physiology, could be related to 
endocrine functions, vascular responses, modulation of the 
immune system and neuroprotection [13–15].
Cannabinoid-induced antinociception acts on the various 
levels of the pain sensory pathway, activating the antinoci-
ceptive pathways that are mediated by cannabinoids. The 
activity at the CB1 receptor system increases in response 
to noxious stimuli. Indeed, the CB1 receptors have been 
identified on primary afferent neurons on both type C and 
type Aβ/δ fibres, dorsal root ganglia, the spinal and terminal 
intrinsic neurons of the dorsal horn of the spinal cord and 
neurons projecting to the brain (medulla rostral ventrome-
dial, periaqueductal grey matter, amygdala, and thalamus).
At the spinal level, the analgesic effect of cannabinoids 
seems to be obtained from the activation of the OP2 opi-
oid receptor. In fact, the analgesic effect is cancelled by the 
intrathecal administration of OP2 receptor antagonists. Peri-
aqueductal grey matter (PAG) is one of the areas that is most 
strongly involved in mediating cannabinoid analgesia. This 
may be due, in part, to the direct inhibition of the release 
of GABA in this brain area and medulla, and, in part, may 
be related to the inhibition of glutamate release. In fact, the 
hyperalgesia induced by the CB1 antagonist is attenuated 
by the administration of NMDA receptor antagonists [46, 
Fig. 1  Simplified scheme representing the pathogenesis of pain fol-
lowing inflammatory disease or nociceptive stimulus, the cytokines 
involved in the process, the descending supraspinal modulation and 
the relive neurotransmitters and endocannabinoid retrograde signal-
ling mediated synaptic transmission. Endocannabinoids are pro-
duced from postsynaptic terminals upon neuronal activation. Natural 
and synthetic cannabinoids act like the two major endocannabinoids 
shown in the scheme: anandamide (AEA) and 2-arachidonolglycerol 
(2-AG). Endocannabinoids, synthesized starting from fatty acids (FA) 
through diacylglycerol lipase (DAGL) and N-acyl phosphatidylethan-
olamine phospholipase D (NAPE-PLD) readily cross the membrane 
and travel in a retrograde fashion to activate CB1 and CB2 located 
in the presynaptic terminals. Activated CB1 will then inhibit neuro-
transmitter (NT) release through the suppression of calcium influx. 
NT can bind to ionotropic (iR) or metabotropic (mR) receptors. 2-AG 
is also able to activate CB1 located in astrocytes. Although endocan-
nabinoid retrograde signalling is mainly mediated by 2-AG, AEA can 
activate presynaptic CB1 as well. Fatty acid amide hydrolase (FAAH) 
found in postsynaptic terminals is responsible for degrading AEA to 
AA and ethanolamine (Et). Inflammation led to release of biochemi-
cal mediators (bradykinin (BK), serotonin (5-HT), prostaglandins etc) 
and the up-regulation of pain mediator nerve growth factor (NGF). 
The substance P (SP) and calcitonin gene-related peptide (CGRP) 
vasoactive neuropeptides, released from sensory nerve, also have a 
role in inflammation. The interaction with opioids, cannabinoids and 
nonsteroidal anti-inflammatory drugs are also represented. Adapted 
from Bruni et  al. [6]; permitted reproduction under the terms and 
conditions of the Creative Commons Attribution (CC BY) license 
(https:// creat iveco mmons. org/ licen ses/ by/4. 0/).
1517Cannabinoid Formulations and Delivery Systems
47]. Cannabinoids activate a midbrain circuit to reduce pain 
sensations in the ventromedial rostrum (RVM) medulla [49]. 
In fact, the inactivation of this region prevents cannabinoid 
analgesia.
The antinociception induced by cannabinoids, at the level 
of the descending pathway, may be related, at least in part, to 
the release of norepinephrine. In fact, it has been shown that 
the antinociceptive effect can be attenuated by the adminis-
tration of yohimbine but is not influenced by methysergide. 
Another analgesic mechanism that is induced by cannabi-
noids may be mediated via the interaction of dopamine and 
D2 receptors as it is enhanced by agonists and attenuated by 
selective antagonists. In addition, the cannabinoid and opi-
oid systems show synergism that is mediated by receptors at 
the spinal and supraspinal levels. At the spinal level, cannab-
inoids activate the OP2 receptor, while opioids activate the 
OP3 and OP1 receptors. At the supraspinal level, synergism 
occurs via the activation of the OP3 receptor, indicating that 
analgesia from morphine, which is mainly mediated by the 
OP3 receptor, can be increased by cannabinoids through the 
activation of OP2 receptors. This synergism explains the 
reduction in opioid dosage when used in combination with 
cannabinoids. THC is capable of reducing the minimum 
effective dose of morphine by 55%, methadone by 75% and 
codeine by 96% [52]. On the other hand, the cannabinoid 
system is larger and occupies more brain areas than the opi-
oid system. However, the absence of specific receptors in the 
brain areas that control breathing, unlike those of morphine, 
prevents the risk of respiratory depression.
2.1  Other Potential or Approved Therapeutical Uses 
of Cannabinoids
In order to allow the reader to have a global view of the 
cannabinoid formulations, which have notably flourished in 
recent years, we also briefly describe other relevant thera-
peutic areas of application.
Therapeutic properties of cannabis plant have been 
known from ancient times and although, in most cases, 
results cannot be considered definitive and there are cur-
rently no pathological conditions for which cannabinoids 
can be considered the first-line treatment, the literature 
increasingly reports studies relating to the medical use of 
cannabis and cannabinoid for relevant diseases but also for 
the patients’ well-being.
Anticancer potential activity of cannabinoids derived by 
observation that alterations of CB1 and CB2 expression 
levels and/or function have been observed in cancers [16]. 
Antineoplastic activity of cannabinoids demonstrated inhi-
bition of growth of several cancer cell lines, and promising 
results have been obtained in animal cancer models (lung, 
breast and prostate and blood cancers). Nevertheless, 
highly heterogeneous cannabinoid receptor expression 
has been reported in several cancers, which it seems, are 
not ubiquitously expressed in all patients [17]. Regarding 
glioblastoma, the most frequent and aggressive malignant 
brain tumour, it found that elevated CB2 expression cor-
related with a higher degree of tumour malignancy. This 
led to the hypothesis that cannabinoids may exhibit effects 
against glioblastoma and this was confirmed by several 
in vivo studies [18].
Multiple sclerosis is an immune-mediated neurological 
disease, which leads to prolonged and progressive physi-
cal, psychological and cognitive disability. Chronic central 
neuropathic pain and spasticity are common distressing 
symptoms that cause disability and a lower quality of life 
[19]. It has been demonstrated that cannabinoids and the 
endocannabinoid system have a role in reducing spasticity in 
animal models, although recent clinical reviews concluded 
that cannabinoids may have a modest effect in the manage-
ment of pain and spasticity in multiple sclerosis [20].
Cannabis galenic preparations as well as single purified 
cannabinoids can also be prescribed for the treatment of sev-
eral neuropsychiatric conditions, such insomnia, depression 
and anxiety, attention deficit/hyperactivity disorder, autism, 
cluster headaches and, restless legs syndrome and Tourette’s 
syndrome [1, 21, 22].
Emerging cannabinoid roles have recently appeared for 
management of associated neuropathological alterations in 
Alzheimer disease [23].
Important clinical results have been reported for cannabi-
noids in treatment of paediatric epilepsy. Therapeutic use 
of cannabis in treatment of infantile spasms has been docu-
mented since 1840 but it was only in 2018 that cannabidiol 
(as Epidiolex marketed medicine) was approved by the FDA 
and then by the EMA as an add-on antiepileptic drug in 
children with Dravet syndrome and Lennox–Gastaut syn-
drome (serious epileptic encephalopathies, generally resist-
ant to treatment). The efficacy of this treatment in reducing 
seizures frequencies and in improving the quality of life in 
childhood epilepsy was shown in recent systematic reviews 
and was summarised by Raucci et al. [24].
The best way to establish a correlation between cannabis 
use and well-being is to measure the health-related quality of 
life (HRQoL), and this should be performed using validated 
questionnaires [25, 26]. HRQoL is defined as “those aspects 
of self-perceived well-being that are related to or affected by 
the presence of disease or treatment” [26, 27].
Considering that chronic diseases, due to their long dura-
tion, can negatively affect HRQoL, this parameter should 
be taken into consideration in clinical studies [28]. Some 
authors have also hypothesised that the use of cannabis may 
lead to a reduction in conventional therapies, which normally 
show several adverse effects. Therefore, an improvement in 
HRQoL could also be linked to the decrease in adverse drug 
reactions [28, 29].
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HRQoL is the most important target for patients in pal-
liative cancer therapy. In palliative care, cannabinoids are 
usefully administered as antiemetics in cases of the nausea 
and vomiting caused by chemotherapy or radiotherapy [30]. 
The antiemetic drugs used to combat nausea and vomiting 
are not always effective and can have side effects on the cen-
tral nervous system, particularly by causing sedation. The 
action of cannabinoids on CB1 localised in the dorsal vagal 
complex of the brainstem is considered to be responsible for 
the antiemetic activity of cannabinoids. There is evidence 
that cannabinoids are more effective at attenuating nausea, 
and FDA-approved dronabinol has therapeutic uses in the 
USA for nausea associated with cancer chemotherapy [31].
Furthermore, cannabinoids have the ability to counteract 
anorexia cachexia and weight loss, as they can act as an 
appetite stimulant in patients undergoing chemotherapy [32].
The reason for this effect lies in the presence of CB1 
receptor in the hypothalamus, the region of the brain that 
controls food intake. Numerous studies have reported the 
role of cannabinoids in appetite stimulation, resulting in 
weight gain, when administered orally at low or moderate 
doses, with minimal side effects.
Another promising application of cannabinoids is the 
therapy of inflammatory bowel disease, especially Crohn's 
disease. Many gastrointestinal processes can be affected 
by cannabinoids because their receptors are distributed 
throughout the human gastrointestinal tract (CB2 is gener-
ally expressed by immune cells and the peripheral nervous 
system, while CB1 is more widely expressed in enteric nerv-
ous system, epithelial cells, myenteric and submucosal plex-
uses and adjacent to motoneurons) [33]. In particular, CBD 
appears to be an attractive therapeutic option, also due to 
lack of central effects. Nevertheless, although many patients 
could benefit from cannabinoid treatment, particularly when 
measuring HRQoL, at the moment, few clinical studies have 
been completed.
It is important to remember that cannabis-derived prod-
ucts (particularly THC, dronabinol, nabilone), are also asso-
ciated with relevant short-term adverse effects including 
drowsiness, dizziness, confusion, hallucinations, euphoria, 
nausea and vomiting, and diarrhoea as reported in clinical 
trials [34]. These adverse effects remain similar across the 
diverse patient populations and to mitigate these effects, 
individual dose titration may be considered.
3  Data Sources and Search Strategy
An electronic search was conducted using several search 
engines: the Chemical Abstract Service Scifinder, which 
indexes Medline and Chemical Abstract reference databases 
and provides a wide range of international patents; Springer 
Nature AdisInsight, which also brings together information 
on drugs in commercial development, deals and key clini-
cal trials; and Scopus (Elsevier). The following clinical trial 
databases were also explored: clinicaltrials.org; anzctr.org.
au; and eudract.ema.europe.eu. To complete the investiga-
tion into patent sources, the Questel Orbit Database was also 
used. Searches were carried out in the period January–April 
2021 with check for updates.
Professional organisation guidelines, documents from 
international medicine institutions (Food and Drug Adminis-
tration [FDA] European Medicines Agency [EMA], Govern-
ment of Canada), and academic websites were also utilised, 
as appropriate.
Regarding selection criteria, the studies were included 
in the review if they described the use of a cannabis-based 
product and/or medication (e.g., dronabinol, nabilone, 
Nabiximols, cannabidiol, Δ9-tetrahydrocannabinol), singu-
larly or in combination with the qualifying condition and its 
synonyms; cannabinoid formulations or cannabinoid dos-
age forms—in different administration routes. Patents were 
also extracted using the name of the applicant companies. 
Furthermore, information related to cannabis for medical 
purposes, standards and analytical methods were extracted 
from German, Swiss and US pharmacopoeias.
Sources of information on cannabinoid use in the treat-
ment of pain were extensively analysed, although other 
common disease states were included. The search period 
spanned mainly from 2018 through to April 2021, for the 
scientific articles, while for patents, the search could cover 
a broader period (last decade), as well as more relevant 
reviews. The articles included were limited to those in the 
English and German languages and, principally, to studies 
conducted in humans.
The authors of this review chose to include cannabis-
based medications and explore the wide range of products 
in industrial development as well as galenic preparations. 
Thus, basic information and descriptions will be detailed. 
However, cannabis preparations that are identified as food, 
food supplements, cosmetics and for recreational use, gener-
ally referred to as cannabis-based products without a stand-
ardised pharmaceutical form, are outside the scope of this 
article.
4  Principal Cannabis Active Agents
Cannabis sativa L. contains a large range of identified 
compounds, although the main active principles are the 
cannabinoids. Phytocannabinoids and terpenoids are syn-
thesised in cannabis in secretory cells inside glandular tri-
chomes and are most highly concentrated in unfertilised 
female flowers prior to senescence [35]. Over 120 different 
phytocannabinoids have been isolated [36], and of these, 
Δ9-tetrahydrocannabinol (Δ9-THC, hereafter THC; CAS 
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1972-08-3) and cannabidiol (CBD; CAS 13956-29-1) are 
the most abundant and widely studied (see structures in 
Fig. 2).
The following are expressed in lower amounts, although 
they are therapeutically promising in some cases: can-
nabinol (CBN; CAS 521-35-7), cannabigerol (CBG; CAS 
25654-31-3), cannabichromene (CBC; CAS 20675-51-
8),), cannabidivarin (CBDV; CAS 24274-48-4), cannab-
igerivarin (CBGV; CAS 55824-11-8), cannabichromeva-
rin (CBCV; CAS 57130-04-8), Δ9-tetrahydrocannabivarin 
(Δ9-THCV; CAS 31262-37-0), and their related acids [37].
While cannabinoids are produced by the cannabis plant 
as carboxylic acids, the carboxyl group is not very stable 
and is easily lost under the influence of light, heat, or pro-
longed storage.
Terpenes are another class of organic components that are 
widely represented in the plant (approximately 140 different 
types). Terpenes that are often encountered in cannabis vari-
eties include the monoterpenes myrcene, α-pinene, β-pinene, 
limonene, terpinolene, while α-caryophyllene, humulene and 
others, present in traces, represent the sesquiterpene fraction 
[38].
Besides cannabinoids and terpenes, cannabis plants pro-
duce interesting polyphenolic compounds called flavonoids 
as well as steroids, pigments and other substances.
From a pharmaceutical point of view, it is important to 
remember that cannabis is hyper-accumulator for heavy 
metals. Furthermore, microbial contaminants, pesticide resi-
dues, and harsh extraction solvents can be also present in the 
extracts. Therefore cultivation, extraction and purification 
steps and analytical methods must meet the current Good 
Fig. 2  Structures of the princi-
pal cannabinoids described in 
the text
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Manufacturing Practice standards. On the contrary, can-
nabinoids produced by synthesis start from a characterised 
starting material and yield high purity products. Frequently 
cannabinoids can also be produced by semi-synthesis start-
ing from precursors extracted from hemp further modified 
by chemical reactions (e.g., dronabinol). Furthermore, sev-
eral novel synthetic derivatives of phytocannabinoids have 
been designed and tested in recent years.
From a physicochemical point of view, pharmacologically 
active cannabinoids are classified as Class II, according to 
the Biopharmaceutics Classification System (BCS) for oral 
drugs, as they have very low water solubility and high lipo-
philicity; CBD, (12.6 mg/L, logP 6.3, pKa 9.29), THC (28.0 
mg/L, logP 6.97, pKa 10.6).
Regarding its elimination route, as outlined by the Biop-
harmaceutics Drug Disposition Classification System 
(BDDCS), cannabinoids belong to Class II, which indicates 
compounds that are poorly water soluble and that are exten-
sively eliminated by metabolism [39]. Indeed, the important 
first-pass effect (liver metabolism) limits the oral dose of 
CBD that reaches systemic circulation by about 75%.
Several recent reviews have thoroughly described the 
pharmacokinetic and biodistribution behaviour of cannabi-
noids [40–43].
5  Galenic Preparations of Cannabis Extracts
In recent years, the official introduction of pharmaceutical 
grade cannabis inflorescences for medicinal use has offered 
medical doctors the opportunity to prescribe, and for phar-
macists to prepare, cannabis-based formulas [44].
In order to provide patients legal access to medical canna-
bis, an ever increasing number of countries have introduced 
specific regulations on this topic [45]. In Europe, for exam-
ple, the United Kingdom (UK), Netherlands, Italy, Germany, 
the Czech Republic, Croatia and Finland have introduced 
specific regulations and guidelines regarding medicinal can-
nabis [44]. The same is true globally in Canada, the USA, 
Israel and Australia, for example [45]. The regulatory frame-
work for cannabis as a pharmaceutical product varies widely 
across the world, but in general, the laws in force in the 
different contexts specify the medical conditions, including 
pain, for which cannabis can be prescribed and which forms 
of administration are allowed [44].
The inflorescences available for medical use are of differ-
ent varieties and are characterised by a different content of 
active molecules. In this regard, it is important to underline 
that the contents of THC and CBD are usually reported on 
the label by manufacturers. Furthermore, the percentages 
of THC and CBD must be understood as referring to the 
“total”, i.e. the sum of the acidic and the decarboxylated 
molecules [46].
The inflorescences, which can be marketed in raw form 
or following granulation, can be smoked, vaporised using 
specially developed devices, or can be subjected to extrac-
tion processes to provide preparations for oral administration 
[44].
The literature reports on the different extraction meth-
ods that can be used on cannabis hemp and on its medical 
use counterpart. The phyto-complex of cannabis plants is 
made up of more than 500 different constituents, of which 
one hundred or more belong to the cannabinoid class [47]. 
Therefore, the applied extraction technique can exert con-
siderable influence on the active molecules administered to 
patients.
The possibility that the co-presence of numerous mol-
ecules, cannabinoids and others, in preparations obtained 
from cannabis and administered to patients may lead to a 
greater effect than the sum of its contributing parts has been 
called the “entourage effect”. This effect was first hypothe-
sised by Mechoulam and Ben-Shabat [48]. Synergy between 
cannabinoids and between cannabinoids and terpenes in 
cannabis has been investigated. Although there are many 
promising studies on this topic, the incomplete understand-
ing of the mechanism behind the entourage effect in can-
nabis preparations makes it difficult to follow regular drug 
development and approval procedures [49–51]. Recently, 
the role of the entourage effect of cannabis-based products 
in pain has been evaluated. Although definitive studies are 
still required, there is increasing evidence to support the 
beneficial effects of plant-derived cannabinoids in providing 
pain relief [52].
Given the widespread interest in the entourage effect, 
several studies have been performed on complex cannabis 
extracts, often called the “full-extracts”. Recently, in order 
to investigate the effect of cannabis extracts on opioid use 
and HRQoL in chronic pain patients, soft gels containing 
CBD, THC, CBDV, CBDA, CBC and a terpene blend were 
administered in a single-arm cohort study. The results sug-
gest that the administered extract allowed patients to signifi-
cantly reduce opioid use, while also providing improvements 
in their HRQoL [53]. The role of cannabis complex extracts 
in pain, particularly of the neuropathic type, has also been 
reviewed, and it was highlighted how several clinical stud-
ies using cannabis extracts have provided promising results. 
On the other hand, some clinical trials have highlighted the 
reduced beneficial effects of purified THC and/or CBD. 
This, according to the authors, underlines the possibility that 
studies using a purified THC or CBD may not truly reflect 
the extracts’ benefits [54].
Regarding the extraction methods, the most widely used 
solvent for plant solid-liquid extraction is ethanol, because 
of its cannabinoid high extraction power; other solvents are 
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generally used for analytical purposes [55, 56]. Ethanol has 
also been reported in the German pharmacopoeia Cannabis 
flos monograph, which describes dynamic maceration as the 
method of choice for cannabinoid extraction [55, 57].
Alternative types of extraction, such as ultrasound-
assisted extraction, microwave-assisted extraction and super-
critical fluid extraction have also been described [55, 56, 
58–60]. All these extraction methods are difficult to apply to 
medical use, because of the costs and the difficulty of their 
preparation in the labs of hospitals and community phar-
macies, which are usually tasked with preparing cannabis 
for medical purposes [61]. Supercritical  CO2 extraction is, 
however, taken into account by the German pharmacopoeia 
Cannabis extractun normatum monograph as the preferable 
method [62, 63].
On the other hand, water has been reported to be a bad 
solvent for cannabinoids, raising the relevant issue of water-
based preparations derived from cannabis, such as decoc-
tion [56, 64–66]. Prescribing a cannabis-based decoction, 
considering the low recovery rates of THC and CBD and, 
consequently, the high volume of preparation that the patient 
would have to ingest, should not be the first choice for can-
nabis-based therapies. More important, only the soluble can-
nabinoids acids can be extracted in water, and these will not 
significantly decarboxylated successively
[67]. Furthermore, the high raw material costs necessary 
to obtain the desired doses of active molecules should be 
seriously taken into account [46].
Cannabis-oil preparation has aroused a lot of interest 
in recent years for two main reasons: its ability to easily 
modulate the dose during therapy, and the better bioavail-
ability of the active components, due to the lipophilicity of 
the formulation [68]. These preparations generally involve 
the use of European Pharmacopoeia grade olive oil, which 
can positively affect the digestibility of the finished product 
as lipid sources, rich in saturated fatty acids, are less sensi-
tive to oxidation phenomena after hot maceration, resulting 
in minimal deterioration during storage [69–71].
In this context, although there are no official shared pro-
tocols, cannabis-based formulations have been prepared on 
prescription by pharmacists in recent years [61]. The meth-
ods for preparing cannabis oils for medical purposes that 
have been developed since 2018 have been summarised in 
Table 1, and some differences have been highlighted. First 
of all, the weight-to-volume ratio between plant material 
and oil can vary from 0.02 to 0.2 g/mL of oil. Furthermore, 
pre-treatment can be applied to the plant material; it is a 
relevant step and may consist of crushing the inflorescences 
in order to reduce their particle size, as well as heating the 
plant material in order to decarboxylate THCA and CBDA 
into the corresponding neutral forms (THC and CBD). The 
decarboxylation process has been recommended as it turns 
the acidic cannabinoids into their neutral counterparts THC 
and CBD, which can be more easily absorbed through the 
intestine [43]. However, some authors have pointed out the 
therapeutic value of acidic cannabinoids [43, 44].
Moreover, different inflorescence maceration times and 
applied temperatures have been applied.
Cannabis oils are usually characterised in terms of their 
THC and/or CBD content. Considering the potential role of 
the “entourage” effect, some extraction methods have been 
developed to preserve the terpenes naturally present in can-
nabis, although there is not yet sufficient evidence for their 
role in therapy [72]. Low temperatures (maximum 115 °C) 
have been applied for this purpose. Low-temperature treat-
ment can also be associated with ethanol co-extraction and 
microwaves [72].
The feasibility of using medium-chain triglycerides has 
also been recently investigated and the results have been 
compared with data obtained from olive oil preparations, 
with excellent results being reported for the quantity and 
stability of the extracted terpenes. However, of course, the 
cannabinoid profile may be affected by the use of these dif-
ferent lipids [70].
Regardless of the interest in terpenes, the effect of adding 
surfactants to water or ethanol has also been investigated, as 
has the use of ultrasound and microwaves, to improve extrac-
tion in oil or ethanol [73].
A great variability in the concentration of active mol-
ecules in the oils has generally been found and this depends 
on the use of different varieties of cannabis and, of course, 
on their possible natural fluctuation in the inflorescences 
[74, 75]. However, the principal variability derives from 
the application of different preparation protocols in phar-
macies [75, 76]. The variability in oil composition means 
that titration is fundamental to prescribing the correct dos-
age. Moreover, it is necessary in order to clarify what mol-
ecules, in addition to THC and CBD, are to be considered 
during titration [75, 77]. The administration of formulations 
that contain known quantities of active molecules is essen-
tial to ensure the uniformity of therapies, which can lead 
to the consequent optimisation of the risks/benefits [78]. 
Furthermore, the need to know the exact composition of 
the preparations is linked to the possibility of evaluating the 
effectiveness of the entourage effect.
In order to respond to the needs of quality control and 
quality standards in herbal products and extracts, a Cannabis 
Expert Panel was convened by USP in 2016 at the direc-
tion of the USP Botanical Dietary Supplements and Herbal 
Medicines Expert Committee. A very important review that 
was recently produced by the Expert Panel clearly describes 
the scientific quality attributes and related standards of can-
nabis [79].
One aspect that is not to be overlooked is the fact that 
the organoleptic characteristics of the oils usually are par-
ticularly unpleasant. In order to facilitate medical cannabis 
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Table 1  Galenic preparations









Olive oil extraction 
conditions
Number of samples Stability tests References
Bedrocan® 1:10 Yes 115 °C, 40 min
145 °C, 30 min
RT
70 °C, 40 min
100 °C, 40 min
100 °C, 120 min
110 °C, 120 min






Bedrocan®;  Bediol® 1:10 Yes 145 °C, 30 min Ultrasound extrac-
tion (35 KHz 30 
min) at RT
Not declared Refrigerator or RT, 
6 weeks
[71]
Bedrocan® 1:10 Yes A: 80% of the inflo-
rescences:
1. 115 °C, 90 min
2. Addition of olive 
oil






5. Heating step: 115 
°C, 30 min
6. Addition of olive 
oil
Mixture of A and 
B: maceration 
under mechanical 
stirring for 24 h at 
room temperature
2 No [72]
Bedrocan® 1:10 Yes 1. Steam distilla-
tion: 100 °C, 120 
min to obtain the 
essential oil
2. Removal of 
residual water 
from the plant 
material
3. Addition of 
olive oil to plant 
material
1. Olive extract 
obtained at 98 °C, 
60 min
2. Addition of the 
essential oil to the 
olive oil extract
2 No [72]
Bedrocan® 1:10 Yes (A) Microwave 
hydro-distillation 
to obtain the 
essential oil: 500 
W for 3 min, then 
320 W for 10 min 
and, finally, 290 
W for 60 min
(B) Removal of 
residual water 
from the plant 
material
(C) Addition of 
olive oil to plant 
material
1. Olive extract 
obtained at 98 °C 
for 60 min
2. Addition of the 
essential oil to the 
olive oil extract
2 No [72]
FM2 1:10; 1:5 Yes 115 °C for 40min
140 °C for 30min
Room temperature
100 °C for 30, 60, 
120 min
> 100 Refrigerator or RT, 
6 months
[46, 78]
Bedrocan®,  Bediol® 1:10 Yes 100 °C, 30 min
125 °C, 30 min
100 °C for 30 min 3 4 °C, 3 months [70]
Bediol®,  FM2®, 
 Bedrocan®
1:50 Yes 120–130 °C, 30 min Microwave assisted 
oil extraction: 90 
°C, 3 min
Not declared No [73]
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consumption by patients, a standard procedure has recently 
been developed for the preparation of hard capsules with 
cannabis oil. Masking the organoleptic characteristics of the 
oil may also have the advantage of allowing the presence 
of a placebo group in a clinical trial. Capsules have been 
selected because this pharmaceutical form can be easily pre-
pared in a reproducible way in a pharmacy [78].
Apart from the literature data on the performance of the 
different applied extraction techniques, the efficacy of the 
magistral formulas also needs to be clinically investigated, 
not only in terms of pain treatment, but also in consideration 
of the fact that prescriptions are usually added to standard 
treatments. There are currently no significant data on the 
clinical outcomes of these preparations, in part, because data 
on the efficacy of the administered preparations are usu-
ally not reported by the literature, although guidelines are 
available for prescribing or preparing magistral formulas. 
This is also true because, in some cases, preparations, such 
as decoctions, are prepared at home by patients, making 
them less standardisable and outcomes difficult to evaluate. 
Consequently, the decoction is performed in different ways. 
According to the most known information, provided by the 
Dutch Office for Medicinal Cannabis to patients, decoctions 
(called “teas”) could be prepared as follows: bring the water 
to a boil and add 1 g/L of cannabis. Lower the heat, cover 
with a lid and allow to simmer gently for 15 minutes then 
remove from heat and filter [80].
Nevertheless, cannabis preparations are usually pre-
scribed for the treatment of several conditions, such as pain, 
cancer, epilepsy, insomnia, depression and anxiety, attention 
deficit/hyperactivity disorder (ADHD), autism, cluster head-
aches and Crohn's disease, irritable bowel syndrome, restless 
legs syndrome and Tourette’s syndrome [44].
The idea of using capsules has also been explored in 
a recent trial in which purified extracts of cannabinoids, 
titrated in THC and CBD, have been added to blends of 
coconut oil, monoglyceride and diglyceride and combined 
with carrageenan to obtain a lipid-based delivery system. 
The aim of the study was to evaluate the effect of dosage-
controlled cannabis capsules in cancer-related cachexia and 
anorexia syndrome in advanced cancer patients. Despite 
various limitations, this preliminary study demonstrated 
weight increases in some patients, highlighting the need for 
a larger study [81].
6  Pharmaceutical‑Grade Cannabinoid 
Formulations
6.1  Oral Administration
The oral administration route of cannabinoids is favoured 
over the other routes because it offers several advantages 
including safety, good patient compliance, ease of ingestion, 
pain avoidance, and the versatility to accommodate various 
types of drugs. Furthermore, exposure time is longer, and 
the side effects are significantly less intense.
Cannabinoids, indeed, have poor oral bioavailability (esti-
mated to be as low as 6% of a similar dose administered 
intravenously). Pure THC and CBD show similar plasma 
concentration-time profiles, with a delay of 120 min before 
reaching peak concentration [42]. Bioavailability increases 
when it is co-administered with food lipids. A cannabis for-
mulation in sesame oil (a vehicle with long chain triglyc-
erides [LCT], containing 42% oleic, 40% linoleic and 16% 
palmitic acids) significantly improved the bioavailability of 
cannabinoids [82].
The contribution of intestinal lymphatic transport is also 
worthy of note in the case of highly lipophilic compounds 
[83]. Indeed, the fatty acids generated by the lipolysis of 
medium and long chain triglycerides undergo several differ-
ent processes: long chain fatty acids are associated to chy-
lomicrons that are secreted into the lymphatic system instead 
of the portal vein. Thus, THC and CBD, used in combination 
with LCT, can bypass the liver, decreasing potential pre-
systemic metabolism [41]. By avoiding loss in pre-systemic 
metabolism in the liver, cannabinoids can reach 22% bio-
availability [84].
The role of high-fat meals on pharmacokinetic behaviour 
is also relevant. A formulation for CBD (administered as a 
single 1500 mg dose at 100 mg/mL in a sesame-oil vehicle) 
showed an absolute oral bioavailability of about 6% after 
intake in the fasting state, while co-administration with a 
high-fat meal would be expected to result in a bioavailability 
of about 25% and in reduced inter- and intra-subject vari-
ability, compared with the fasting state [40]. Moreover, THC 
showed similar bioavailability behaviour when administered 
with sesame oil [43].
Furthermore, the potential role of cannabinoid metabo-
lites, especially active metabolites such as 7-hydroxy-CBD, 
should be considered, as outlined in recent studies in sub-
jects with renal or hepatic impairments [85–87].
Oils that are formulated into capsule pellets and solid 
tablets currently allow pharmaceutical-grade compounds to 
be conveniently and accurately dosed.
Two important considerations to make when evaluating 
cannabinoid formulations are the pharmacokinetic goal and 
intended use. For example, if the indication is to treat acute 
pain, then a faster Tmax and higher Cmax may be desirable, 
while also potentially helping to decrease the risk of over-
dose via premature repeat self-administration. Alternatively, 
a larger AUC may be preferable for use as a chronic treat-
ment if a user follows a regular dosing schedule.
Nevertheless, an ideal oral dosage form that has consist-
ent delivery and high bioavailability is not yet available 
and is therefore warranted. Many companies have invested 
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huge amounts of effort into improving pharmaceutical oral 
dosage. The different strategies taken have been detailed 
below, and have been marketed. The most advanced for-
mulations have been summarised in Table  2. Table  3 
summarises the ongoing clinical trials on pain treatments. 
Only the most recent reports on active research and the 
latest development phases are described. To complete the 
information and allow the reader to move more deeply into 
the composition and technology involved in the formu-
lation procedures, the most significant data from related 
patents are also reported.
Further improvements can be expected with the use of 
nanotechnology sciences as summarised in Sect. 6.1.1.
Two pharmaceutical preparations of purified THC are 
currently available. Dronabinol is the semi-synthetic form 
of THC, which is available in the capsule form  Marinol® 
(Abbvie Inc. US) and as a solution  Syndros®, which was 
originally produced by Insys Therapeutics US and is now 
marketed by Benuvia Therapeutics, USA.
Marinol® is supplied as round, soft gelatin capsules that 
either contain 2.5, 5 or 10 mg of dronabinol formulated in 
sesame oil.
A  Syndros® solution contains 5 mg of dronabinol in 1 mL 
of the inactive ingredients: 50% (w/w) dehydrated alcohol, 
polyethylene glycol 400, propylene glycol, plus preserva-
tives and antioxidants.
Marinol® and  Syndros® were approved by the FDA for 
the treatment of anorexia associated with weight loss in 
patients with AIDS. It has also been approved for the nau-
sea and vomiting associated with cancer chemotherapy in 
patients who have failed to respond adequately to conven-
tional antiemetic treatments (NDA 18-651/S-021).
In Europe, dronabinol and CBD received an initial evalu-
ation as orphan drugs for the treatment of glioma in 2015, 
but this was later withdrawn. Medicinal products that con-
tain dronabinol are available in few EU countries (for com-
passionate grounds and for magistral preparations). Two 
ongoing studies appear in the EU Clinical Trials Register: 
one for patients with pancreatic cancer in the palliative state 
(2017-000530-54), and the second on the efficacy and safety 
of THC in behavioural disturbances and pain in dementia 
(2011-005289-39).
In Europe, a liquid formulation of dronabinol (named 
BX 1), produced by Bionorica SE (D), began a Phase III 
trial to evaluate the efficacy and safety as adjuvant ther-
apy to first-line standard chemotherapy in patients with 
metastatic pancreatic cancer (n = 140) for the improve-
ment of chemotherapy- and tumour-related symptoms 
(EudraCT2019-000616-28; NCT03984214). A Phase III 
trial was set up to evaluate the safety and efficacy of dron-
abinol in patients (n = 548) with spasticity due to multiple 
sclerosis (EudraCT2018-000001-23; NCT03756974). More 
recently, in June 2020, a Phase II trial for post-traumatic 
stress disorders was devised in collaboration with Charité 
University (Berlin, D) (NCT04448808).
A low-dose oral formulation of dronabinol is being devel-
oped by RespireRx Pharmaceuticals (USA), in collaboration 
with the University of Illinois and Northwestern University, 
for the treatment of obstructive sleep apnoea (OSA). This 
therapy was previously being developed by Pier Pharma-
ceuticals (USA) as a pellet formulation that combined dron-
abinol and sodium lauryl sulfate (1:1) plus inert excipients. 
The drug is administered orally as an instant-release formu-
lation, 60 minutes before bedtime. Clinical development is 
underway in the USA. Although no clinical trials have been 
reported in Letendre’s patent, a dose of 2.5 mg of THC was 
claimed to provide a significant therapeutic effect (reduction 
of sleep apnoea) [88].
Namisol™ is the name of an oral tablet formulation of 
dronabinol that is developed by Echo Pharmaceuticals b.v., 
(NL). This was produced using Alitra™, an emulsifying 
drug delivery technology. This technology involved the 
preparation of THC microgranules (size 30 micron) with 
the surfactant sucrose monolaurate (about 7% w/w), to 
enhance solubility, and then tableting with other excipients 
[89]. Klumpers et al. have reported pharmacokinetic/phar-
macodynamic evaluations, indicating that the pharmacoki-
netic differences after oral and sublingual (crushed tablets) 
administration were small [90]. Nevertheless, this formula-
tion showed a short time to reach maximal THC concentra-
tion (39–56 min) in comparison to other cannabinoid for-
mulations [91]. Safety and tolerability were also reported, as 
well the pharmacodynamics (n = 12) [92]. Interestingly, the 
effects of THC were smaller than expected for older people. 
A clinical trial on postoperative pain concluded in 2014, and 
this formulation was recently planned for study in a Phase II 
trial for anorexia in Australia (ACTRN12619000491167).
Nabilone (Cesamet™ from Bausch Health Companies) is 
an orally active synthetic cannabinoid derivative that differs 
structurally from THC as its C-ring is saturated and contains 
a C-9 ketone group (Fig. 2). Nabilone is available, with poly-
vinylpyrrolidone and starch excipients, as a capsule (1 mg of 
drug) and has been marketed in the USA since 2006 for the 
treatment of chemotherapy-induced nausea and vomiting in 
patients who have not responded to conventional antiemetic 
treatments [93].
Cyclodextrins, from a pharmaceutical point of view, 
are importantly used for enhancing the aqueous solubility 
of poorly soluble drugs, improving stability and masking 
the unpleasant taste/odour of a formulation [94]. A fast-
disintegrating, controlled-release formulation of nabilone 
 (Canemes®) is being developed by AOP Orphan Pharma-
ceuticals (AT) for the treatment of spasticity-associated 
pain and non-motor symptoms associated with Parkin-
son’s disease [95]. AOP Orphan Pharmaceuticals is the 
proprietor of a formulation in which randomly methylated 
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β-cyclodextrin (β-CD) inclusion complexes of nabilone 
significantly increased the aqueous solubility and bioavail-
ability of the drug. Of the tested CDs, randomly methyl-
ated β-CD was found to be preferable [96]. A pilot Phase 
II trial of  Canemes® for pain was initiated in 2016 in Aus-
tria (EudraCT2015-004227-31), while Phase III develop-
ment is underway in Austria for Parkinson’s disease in the 
elderly (EudraCT2017-004253-16).
It is important to note that the chemical derivatisation of 
CDs may improve their water solubility (2-hydroxypropyl-
β-CD has aqueous solubilities of over 500 mg/mL) and can 
also modulate the binding affinities of the hosts for guest 
molecules that bind to the hydrophobic cavity of CDs [97]. 
A sulfoalkyl ether derivative further improves their aque-
ous solubility. In a patent from Vireo Health LLC (USA), 
the water solubility of cannabinoids was enhanced by com-
plexation with sulfoalkyl-β-CD, and again further by the 
presence of Cremophor EL (polyoxyl-35 castor oil) [98].
Now moving to CBD-based products, the best-known 
marketed medicine is  Epidiolex® (from GW Pharmaceu-
ticals plc, UK). It is a liquid pharmaceutical-grade for-
mulation of purified CBD containing 100 mg/mL drug 
dissolved in sesame oil and 10% ethanol.  Epidiolex® has 
been approved in the USA and Europe as an adjuvant treat-
ment in Dravet syndrome, Lennox-Gastaut syndrome and 
severe myoclonic epilepsy in infancy (aged 2 years and 
above). Results from double-blind, placebo-controlled 
trials have recently been published [99–101]. The same 
formulation was also approved by the EMA in 2019 (with 
name Epidyolex) for the same indications, except that reg-
ulatory approval in Europe is limited to patients receiving 
concomitant therapy with clobazam [10].
As reported in the summary of product characteristics, 
the role of patient’s diet is relevant. Indeed, taking CBD 
with alcohol caused enhanced exposure to CBD, with a 
63% greater AUC. Moreover, the co-administration of 
CBD (750 or 1500 mg) with a high-fat/high-calorie meal 
increased the rate and extent of absorption (5-fold increase 
in Cmax and 4-fold increase in AUC).
Clinical development is underway in a number of coun-
tries for the treatment of several diseases/symptoms: cer-
ebral ischaemia, epilepsy, infantile spasms, opioid abuse, 
heroin-related disorders, Parkinson's disease, Rett syn-
drome, schizophrenia, and tuberous sclerosis. Preclinical 
development is also underway for Duchenne muscular 
dystrophy and ovarian cancer in the UK.
GW Pharmaceutics is currently enrolling patients 
(NCT03891264) in Phase IV research to evaluate the 
presence of neuroinflammation in the brains and spinal 
cords of patients with low back pain, and whether CBD 
effects levels of neuroinflammation. Further clinical trials 
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Table 3  Ongoing clinical trials of cannabinoids and pain in detail
Clinical trial identifier Study title Sponsor Active substance Formulation/route Phase (estimate com-
pletion)
NCT02460692 Dronabinol and 
vaporised cannabis 








NCT04298528 THC post-operative 




THC, dronabinol Oral III (2024)
NCT03978156 THC pain and 
inflammation in 
adults living with 
sickle cell disease
Yale University THC, dronabinol Oral I (2021)a
NCT03099005 Effect of cannabis 
and endocan-















Bionorica SE THC dronabinol Oral III (2022)
NCT04448808 Nightmares in post-
traumatic stress 
disorder
Bionorica SE THC Oral II (2022)
NCT03564548 Cannabinoids versus 
immediate-release 




Tetra Bio-Pharma THC (PPP011) Inhalation II (2022)
NCT03763851 THC CBD and radia-
tion therapy for 
the management 
of pain
Tetra Bio-Pharma THC CBD (PPP005) Oral II (2018) Terminated 
(due to mycotoxin 
potential contami-



















Knop Laboratorios THC CBD Oral II (2020)
NCT02359123 Improve quality of 




Cannabis oil Oral n.a. (2018)
NCT04195269 Osteoarthritis of the 
knee pain
Pure Green THC CBD Sublingual II (2020)
NCT04091789 Treatment of dys-
menorrhea
Pure Green THC CBD Sublingual II (2020)
NCT04527003 Endometriosis pain Milton S. Hershey 
Medical Center
CBD Sublingual III (2022)
NCT04001010 Cachexia progres-
sion/pain
Tetra Bio-Pharma THC CBD Inhalation III (2021)
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after surgery, as well as in acute and chronic diseases, are 
reported in Table 3
GW Pharmaceutics have recently filed a series of pat-
ents on the oral delivery of cannabinoids, both as single 
agents and in combinations [102–104]. The cannabinoids are 
preferably loaded into micelles using non-ionic surfactants 
(e.g., macrogolglycerol hydroxystearate) and administered 
as oral aqueous formulations. Improved biodistribution in 
healthy subjects of 2-fold Cmax and 1.21-fold AUC have 
been reported. Moreover, an oral gel formulation has been 
reported in which cannabinoids are melted with poloxamers 
(poloxamer 124 and poloxamer 188 are preferred) and then 
filled into HPMC, gelatin and soft-gelatin capsules.
An oral CBD oil formulation (CardiolRx™) is being 
developed by Cardiol Therapeutics Inc. (CA). The FDA 
very recently (September 2020) approved an IND applica-
tion for a Phase II/III trial for this oral formulation, taken 
with food, to prevent cardiovascular complications in hospi-
talised patients with a confirmed diagnosis of SARS-CoV-2 
infection in the previous 24 h and who have pre-existing 
IV intravenously, n.a. not available data, NYR not yet recruiting, obs observational study
a Some studies are now suspended or relocated due the Covid-19 pandemic. The date of search update for the reported studies was May 8th, 2021
Table 3  (continued)
Clinical trial identifier Study title Sponsor Active substance Formulation/route Phase (estimate com-
pletion)
EUdraCT2017-000530-54 Cannabinols in 
patients with pan-




THC dronabinol Oral n.a. (ongoing)




CBD Oral n.a. (2019 completed)
EUdraCT2011-005289-39 THC in behavioral 




THC Namisol Oral II (ongoing)
NCT04099355 Dronabinol on post-
surgical pain
New York State Psy-
chiatric Institute
THC dronabinol Oral I (2023)
NCT03661892 Decreasing use of 





Syndros dronabinol Oral (With high-fat) 1 (2020)





Cannabis edible Oral Obs (2022)
NCT03215940 Treatment of chronic 
pain
University of Utah THC dronabinol Oral I (2022)




Unity Health Toronto CBD Oral II/III (2022)
NCT04387617 Postoperative pain 
after ureteroscopy 
for urinary calculi
Mayo Clinic CBD Oral II (2021)
NCT04729179 
EudraCT2019-002394-59





CBD Oral III (2023)
NCT04587791 CBD in opioid use 
and chronic pain
Yale University CBD Oral Safety (2020) NYR
NCT03984565 Sublingual canna-
bidiol for chronic 
pain
Staci Gruber, Ph.D., 
Mclean Hospital
CBD Sublingual II (2020) NYR
NCT01595620 Human experimental 
pain models
Yale University THC IV n.a. (2021)
EudraCT 2019-001861-33 Cannabis-opioid 
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cardiovascular disorders and/or significant risk factors for 
cardiovascular disorders (NCT04615949). Important to note 
that, very recently, the 7-hydroxy-CBD was found to be able 
to promotes the host innate immune response and thus may 
be proposed as potential therapeutic treatment for COVID-
19 at early stages of infection [105].
An interesting, although challenging, technology that is 
based on co-crystallisation has been developed by Artelo 
Biosciences Inc (USA) in order to improve the bioavail-
ability of CBD [106]. The co-crystals consist of the active 
pharmaceutical ingredients and one, or more, unique crystal-
line co-formers (which can be another active substance) that 
modify the material properties whilst retaining the intrinsic 
pharmacological activities of the drugs [107].
Co-crystallisation is a useful, although rarely exploited, 
method for improving the physicochemical properties of 
constituent active pharmaceutical ingredients and for over-
coming problems with drugs by improving their biophar-
maceutical properties. In an interesting article, Almansa 
et al. have described the potential role of this approach in 
the search for a multimodal therapy for pain treatment [108].
Artelo Biosciences have made use of the co-former tetra-
methylpyrazine (also called ligustrazine), a plant-derived 
compound from the Ligusticum striatum DC (= L. chuanx-
iong) that is widely used in Chinese medicines. Preclinical 
development is focused on post-traumatic stress disorder, 
inflammatory bowel disease, stroke, and rare diseases.
Regarding the solid-state behaviour of CBD, amorphous 
CBD is more soluble in water than its crystalline form, but it 
tends to recrystallise. In order to stabilise amorphous CBD, 
three strategies based on different compounds were pro-
posed; cyclodextrins, mesoporous silica and water-soluble 
polymers were processed using different preparation tech-
niques. Then, several parameters (drug loading, aqueous sol-
ubility, final stability, ease of translating for large-scale drug 
production) were evaluated for each formulation, showing 
that all the approaches stabilised the CBD amorphous form 
for at least two months. However, other characteristics, such 
as drug loading, dissolution rate and suitability for scale up, 
differ for each approach [109].
A tablet formulation to improve the bioavailability of 
CBD, designated as  Arvisol®, is being developed by Echo 
Pharmaceuticals (NL). This formulation is designed for the 
treatment of neurological diseases, including Rett syndrome, 
schizophrenia, and epilepsy [110, 111]. Tablets and granu-
lates are prepared, in a model composition, using the wet 
granulation process by combining CBD (6.7% w/w), sucrose 
monolaurate (13.3%), ascorbic acid (0.7%) and lactose. The 
granulate was blended with excipients and compressed into 
tablets for oral use. Pharmacokinetic evaluations showed a 
relevant (cited to be 100-fold) improvement in AUC, com-
pared to capsules loaded with CBD powder, for a 200 mg 
dosage of the drug.
Another interesting, but expensive and highly challeng-
ing, approach is the chemical modification of CBD in order 
to improve solubility, using the synthesis of prodrugs or 
conjugates that link two molecular entities. Kalytera Thera-
peutics, now Claritas Pharmaceuticals (IL), is developing 
a CBD/naproxen conjugate compound for the treatment of 
acute and chronic pain. The non-psychotropic, oral analge-
sic has a cannabinoid component that acts as a cannabinoid 
receptor agonist, and targets the alpha3 glycine pain receptor 
in the spinal cord. When activated, the alpha3 glycine recep-
tor blocks pain signals from being sent to the brain. The nap-
roxen component blocks the synthesis of the pain-inducing 
prostaglandin molecule PGE2 (dinoprostone). Although the 
initial route of administration will be oral, Claritas is also 
seeking to develop an intravenous formulation of the com-
pound. Early research is underway in the USA [112, 113].
The company was also developing other synthetic deriva-
tives of cannabinoids, (in particular CBD) that were struc-
turally modified to enhance solubility in water for improved 
potency (e.g. as phosphonate prodrugs) [114]. These were 
being developed for the treatment of bone fracture, but the 
company has recently discontinued the development of three 
candidates.
An oral formulation of CBD has also been evaluated 
for use as prophylaxis for Graft-Versus-Host Disease 
after allogeneic haematopoietic stem-cell transplantation. 
Clinical development is underway in Australia and Israel 
(NCT03840512, ACTRN12619000623190).
Diverse Biotech Inc. (USA) is also developing CBD con-
jugates for the treatment of cancers. The cannabinoid is the 
core component, and new chemical entities that are theoreti-
cally more efficacious and less toxic are in development via 
combinations with other targeted molecules through conju-
gate chemistry [115]. Preclinical development is underway 
in the USA.
So-called TurboCBD™ has been proposed by Lexaria 
Bioscience Corp. (CA). Capsules with the following com-
position, CBD in hemp oil added to a high proportion of 
American ginseng and Ginko biloba extracts, have been 
made. Formulation is based on DehydraTECH™ delivery 
technology, by Poviva Corp., which includes a patented pro-
cess by which long-chain fatty acids, high in oleic acid, are 
associated with CBD using a dehydration process procedure 
[116].
The results of a clinical trial on TurboCBD™, in com-
parison with the CBD in hemp oil, on 12 healthy participants 
in a double-blind, placebo-controlled, cross-over design have 
been reported by Patrician et al. [117]. The incorporation of 
TurboCBD™ improved CBD bioavailability by 111%, com-
pared with an equivalent generic 90 mg dose, but not with a 
half dose. The authors stated that TurboCBD™ also exhib-
ited a potential advantage over CBD in gelatin matrix pel-
lets, with a Cmax time of 120 min, in comparison to 3–3.5 h. 
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The mechanism for this effect is unclear, but the authors 
believe that the presence of long-chain fatty acids, associ-
ated with CBD using the dehydration processing technique, 
allowed higher concentrations of CBD to enter the circula-
tory system, perhaps by bypassing first-pass liver metabo-
lism. Indeed, lower metabolite levels of 7-hydroxy-CBD and 
7-CBD-carboxylic acid were detected (although in very few 
subjects). A clinical trial in which TurboCBD™ is used as 
dietary supplementation is ongoing (NCT03295903).
The DehydraTECH™ delivery technology has recently 
also been proposed as a means for the transdermal delivery 
of CBD and other lipophilic substances [118].
An oral formulation of CBD as a nanoemulsion has 
also been reported in a recent patent by the same authors 
who describe a composition made up of lactose monohy-
drate powder, as a base substrate, and highly purified CBD 
crystals and sunflower oil in a 1:1 ratio [119]. A surfactant, 
polysorbate 80, has also been added to an aqueous phase of 
quillaja, obtained from Quillaja saponaria. This extract is 
rich in saponins, mainly surfactants, but has a wide range 
of biological activities and is approved for use as a food 
additive in many countries and as a vaccine adjuvant [120]. 
Furthermore, a homogenisation step is used to achieve the 
size reduction required.
A CBD oral formulation (named PTL 101) for the treat-
ment of intractable epilepsy is being developed by MMJ 
PhytoTech Ltd (AU). PTL 101 capsules are made from a pro-
prietary formulation developed using Satipharm's  Gelpell® 
product technology [121]. In detail, doses of 10 to 100 mg 
CBD, dissolved in oil, were added to a hot gelatin solu-
tion, then cooled and dried to produce gelatin pellets, which 
were finally loaded into hard gastro-resistant capsules. The 
soluble gelatin polymer was used to promote dispersion 
by producing a microemulsion in situ, which is expected 
to enhance the bioavailability of the CBD, while avoiding 
punctual irritation of the gastric mucosa. Clinical develop-
ment, underway in Israel (NCT02987114), has demonstrated 
interesting reductions in seizures in paediatric patients with 
treatment-resistant epilepsy over a 12-week period [122]. A 
pharmacokinetic study showed that the CBD, administered 
under fed conditions, provides a relevant improvement in 
AUC (134% for 100 mg dose), compared to an oromucosal 
spray [123].
CBD oral formulations have been developed by Stero 
Biotechs as an adjunctive treatment to reduce side effects 
and the need for steroid therapy [124]. The product (ST 101) 
is made up of CBD dissolved in olive oil at a concentration 
of 2.5% and has been evaluated for autoimmune hepatitis 
and Crohn's disease treatments (NCT04056442). Another 
CBD product is being developed for the treatment of chronic 
urticaria. Clinical development is underway in Israel.
A particular host matrix for the incorporation of CBD, 
in the form of an inclusion complex with β-CD, has been 
fabricated by combining pectin and honey to obtain non-
toxic 3D printable inks that form solid structures upon dry-
ing. The fate of CBD was evaluated in different environ-
ments (simulated gastric fluid, simulated intestinal fluid, and 
simulated colonic fluid). The highest CBD release rates were 
obtained in the simulated colonic environment medium, in 
which pectin is expected to be fully degraded by enzymes. 
The interest in this 3D printing process relies on the pos-
sibility of fabricating personalised food grade CBD dosage 
forms [125].
Studies of the inclusion complexes of native CDs with 
CBD showed that the water solubility increased thanks to the 
formation of 1:1 (α-CD), 2:1 (β-CD) and 2:1 (γ-CD) host-
guest inclusion complexes [126]. The energetic and ther-
modynamic aspects of the CBD-CD interaction in aqueous 
solution were deeply analysed and the authors observed that 
the degree of CBD-CD complexation at four temperatures 
values depended on the medium; it is weaker at increased 
temperatures, except for CBD-γ-CD whose complexation 
is practically insensitive to temperature changes, indicating 
that the γ-CD complex is more stable than the others [127].
An interesting recent analysis of five oral CBD formula-
tions has been described by Williams [128]. A dose of 30 
mg CBD was tested as a solid in suspension in water (code 
203), with oil and starch (code 472), in an oil solution (code 
178), as a liquid formulation with Quillaja extract (20% 
CBD, code 340) and with gum Arabic (5% CBD code 707). 
This last formulation appeared to be superior to most of the 
others. Indeed, it generally evoked the fastest Tmax, greatest 
Cmax, and largest AUC. This is also confirmed in light of the 
majority of the data available in literature on oral CBD. Only 
when CBD was formulated in a self-emulsifying delivery 
system (see next section) was higher Cmax obeserved despite 
a smaller dose (25 mg) [129]. Interestingly, Williams also 
presented the majority of available pharmacokinetic data 
now available (year 2020) for orally administered cannabi-
noids. This information is considered useful for the reader 
and is fully extracted and shown in Table 4.
A pain therapeutic drug that contains CBD and THC is 
being developed by AusCann Group Holdings Ltd (AU), 
with a clinical trial underway in Australia. In April 2020, a 
Phase I trial was initiated to evaluate the pharmacokinetics 
of a single dose of two formulations of an orally adminis-
tered CBD/THC combination (ACTRN12620000462987). 
The randomised, open-label crossover trial has enrolled 28 
fed healthy volunteers in Australia, where capsules con-
taining (ratio 1:1) 2.5 mg and 10 mg formulations were 
administered. Two patents on solid cannabinoid compo-
sitions have recently been filed by AusCann [130, 131] 
where solid self-emulsifying compositions, which contain 
either a single or a blend of cannabinoids, were made up 
of medium chain triglycerides (MCT), surfactant Cremo-
phor EL and colloidal anhydrous silica. A chewing gum 
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composition with controlled release that combines the two 
cannabinoids (ratio 1:1) at a dosage of 5 mg is being devel-
oped by Axim Biotechnologies Inc. (USA) for the treat-
ment of patients suffering from multiple-sclerosis-asso-
ciated pain and spasticity, Parkinson's disease, dementia, 
restless leg syndrome and post-herpetic neuralgia. Clinical 
development is underway in the USA, as is preclinical 
development for post-herpetic neuralgia and psychotic 
disorders. Nevertheless, no recent reports of development 
for Phase I developments have been identified. Patents on 
the co-administration of cannabinoids and opioid agonists 
and/or antagonists have also been reported [132–134].
An analogous orally administrable formulation has also 
been filed by Greenspoon [135], as AX 1505. This is a sus-
tained-release, floating-capsule phytocannabinoid-based 
therapeutic, developed by Axim Biotechnologies for the 
treatment of Crohn's disease. Preclinical development is 
underway in the USA, but, as of December 2020, no new 
reports of development have been identified.
Table 4  Comparison of the pharmacokinetic parameters of preparations proposed by Williams et al with previously reported studies of ingest-
ible cannabinoids
The Table appeared in the article by Williams et al: “Comparison of Five Oral Cannabidiol Preparations in Adult Humans: Pharmacokinetics, 
Body Composition, and Heart Rate Variability” Pharmaceuticals 2021, 14, 35. Permitted reproduction under the terms and conditions of the 
Creative Commons Attribution (CC BY) license (https:// creat iveco mmons. org/ licen ses/ by/4. 0/)





T1/2 (h) Ka (1/h) Ke (1/h) Vd (L)
Oral capsule (CBD + THC) 5.4 mg 0.99 0.93 4.35
Oral capsule (CBD + THC) 5.4 mg 1.0 0.95
GW oral capsule (CBD + THC) 10 mg 1.27 2.47 5.76 6.03 1.09
Oral capsule (CBD + THC) 10 mg 1 2.1 6.9
PTL101 CBD oral capsule 10 mg 3 3.22 9.64 10.31 2.95 0.1
PTL401 (CBD + THC) oral capsule 10 mg 1.25 2.94 9.85 10.52 3.21 0.29
Oral capsule MCT-CBD 25 mg 3.0 3.05 9.51 19.23
Oral capsule SEEDS-CBD 25 mg 13.53 27.15 32.63
Caliper Foods CBD water soluble 30 mg 0.9 2.82 6.80 7.94 2.54 1.68 0.66
Caliper Foods CBD lipid soluble 30 mg 1.5 0.65 1.51 1.64 2.30 1.14 0.72
Preparation 178 CBD 30 mg 3.29 2.20 4.58 – – 0.32 - –
Preparation 203 CBD 30 mg 3.39 1.29 2.30 – – 0.24 - –
Preparation 340 CBD 30 mg 1.28 3.54 7.81 13.81 2.20 1.19 0.40 7428
Preparation 472 CBD 30 mg 1.53 2.88 6.32 9.96 5.18 1.87 0.27 20,178
Preparation 707 CBD 30 mg 0.70 5.57 9.12 10.77 1.42 1.43 0.56 8024
PTL101 CBD oral capsule 100 mg 3.5 47.44 150 153 3.59
(Epidiolex®) 200 mg 2.3 148.0 449 474 8.58 4105
(Epidiolex®) 200 mg 2.5 200.0 671 600 15.5 6661
(Epidiolex®) 200 mg 2.0 172.0 530 522 14.6 7778
(Epidiolex®) 200 mg 2.5 155.0 532 601 13.1 6016
(Epidiolex®) 200 mg 2.5 153.0 464 499 11.2 5800
GW oral CBD capsule 400 mg 3 181.2 704
GW oral CBD capsule 400 mg 1.5 114.2 482
(Epidiolex®) 750 mg 4.0 187.0 1077 1190 39.7
GW oral CBD capsule 800 mg 3 221.1 867
GW oral CBD capsule 800 mg 4 157.1 722
GW oral solution 1500 mg 4 292.4 1517 1618 14.43 20,963
GW oral solution 1500 mg 3.5 335.4 1987 2198 30.33 34,101
(Epidiolex®) 1500 mg 6.13 524.5 2650 2713
GW oral solution 3000 mg 5 533.0 2669 2802 14.39 23,357
GW oral solution 4500 mg 5 722.1 3215 3426 16.61 36,575
(Epidiolex®) 4500 mg 4.07 426.9 2339
GW oral solution 6000 mg 5 782 3696 3900 15.42 42,849
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An oral, fixed-dose combination of CBD and THC, 
designated as BCT 521, has been investigated by Beck-
ley Canopy Therapeutics (UK); a Phase I/II trial has been 
completed and an evaluation of the efficacy and safety for 
pain associated with cancer in patients who have already 
received standard-of-care treatment with opioids has been 
performed (EudraCT2019-001382-32; BCT-521-201). The 
randomised, double-blind, placebo-controlled trial was initi-
ated in November 2019 and enrolled 260 patients in Poland. 
The primary endpoint is a change in the average pain score 
over 24 h from the start of titration to the end of treatment.
A CBD:THC fixed-dose combination is also being 
developed by Knop laboratories (Chile) for the treatment 
of fibromyalgia. The candidate is formulated as an oral 
liquid, containing 1 mg of THC and 0.45 mg of CBD per 
drop. Clinical development is underway in Chile (Phase II) 
(NCT04239469).
A particular CBD:THC formulation is being developed 
by Intec Pharma (IL) for the treatment of various indications 
including pain and fibromyalgia. The therapeutic product 
will be developed utilising a multi-layered, biodegradable, 
gastro-retentive drug formulation named Accordion Pill™. 
Accordion Pill™ technology is a polymeric platform that 
encases a drug preparation and is folded into an accordion-
like shape in a standard-sized regular oral capsule [136]. 
The cannabinoids are emulsified as nano or micro self-emul-
sifying delivery system (see next section) with a caprylo-
caproyl macrogolglyceride surfactant, which is also an effi-
cacious intestinal permeation enhancer [137], in a mixture 
of hydroxypropyl cellulose and oil, and are then dried to a 
dry film (inner layer). A swelling membrane composed of 
PEG, hydroxypropyl cellulose and polymethacrylate poly-
mers, a frame film (polymethacrylate polymers and PEG) 
with a supra-outer film containing THC-CBD and celluloses 
constituted the full structure of the accordion. Furthermore, 
an assembly process in which the different layers are stacked 
and assembled together in a precise order is required. The 
final laminates are folded in an accordion-like configuration 
using a folding apparatus and are inserted into a hard-gela-
tin capsule after folding. After the capsule dissolves in the 
stomach, the accordion unfolds and can remain in the stom-
ach for extended periods of time, beyond those observed 
with standard capsules or tablets. While it is in the stomach, 
the drug is released in a continuous and controlled man-
ner, which optimises absorption into the blood stream. As 
a result, it is thought that the Accordion Pill™ formulation 
will address the disadvantages that are associated with can-
nabinoid therapies, such as delayed onset and short duration 
of effect, drug exposure variability, and that it may signifi-
cantly increase patient compliance due to less repeated dos-
ing. Clinical development is underway in Israel [138].
Hardy and colleagues have recently described (clini-
cal trial ACTRN12619000037101) a placebo-controlled 
ongoing clinical trial to evaluate the efficacy, safety and 
acceptability of 1:1 THC/CBD for symptom relief in 
advanced cancer patients (n = 150) [139]. An oral oil formu-
lation was administered at a concentration of 10 mg/mL and 
a dosage range from 2.5 mg to 30 mg/day for a maximum 
of 28 days. The primary outcome is the change from base-
line as measured by the Edmonton Symptom Assessment 
Scale total symptom distress score at Day 14. It assesses 
both physical and psychological symptoms, plus general 
wellbeing. Recruitment is expected to continue until the 
end of 2021.
6.1.1  Nanotechnology‑Based Approaches for Oral Delivery
In general, due to the high lipophilicity of cannabinoids, 
encapsulation in tailored nanosystems may potentially 
achieve several goals, such as a gradual release, flavour 
masking, superior oral bioavailability and higher physical 
stability than conventional formulations [140]. Although 
several strategies based on known technologies such as 
liposomes, polymeric nanoparticles etc. are still debating 
and in preclinical tests, one of the most interesting and 
profitable approach is represented by the self-emulsifying 
systems.
Self-emulsifying drug delivery systems (SEDDS) have 
been in development since the 1980s and have improved 
to overcome the low bioavailability and poor solubility of 
hydrophobic drugs, such as CBD. SEDDS are lipid-based 
nanosystems that can be easily formed by simply mixing 
drug, lipids and a relatively high concentration of emulsi-
fiers, usually with one or more hydrophilic co-solvents/co-
emulsifiers. This mixture produces oil-in-water emulsions 
or microemulsions upon gentle agitation, followed by dilu-
tion with an aqueous phase. SEDDS are therefore interest-
ing from an industrial point of view, since large batches 
can be prepared without any sophisticated technology. This 
approach is employed with success and is a commercially 
available system for BCS Class II (low solubility, high per-
meability) and class IV (low solubility, low permeability) 
drugs [141].
For a wider recent view of these systems, the reader can 
find an entire issue of Advanced Drug Delivery Reviews 
devoted to this topic [142]. This technique is one of the most 
common approaches in cannabinoid delivery and its applica-
tions will be described below.
SEDDS typically produce emulsions with a droplet size 
of 300 nm, while the droplet size is below 200 nm in self-
nanoemulsifying drug delivery systems (SNEDDS) and a 
lower quantity of surfactants is used [143]. SNEDDS have 
been used as advanced lipid-based formulations to improve 
solubility and contribute to the lymphatic absorption of can-
nabinoids; some of these approaches have been patented in 
recent years, differing from each other in composition and 
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manufacturing procedures [144–146]. Indeed, the compo-
sition of SEDDS greatly influences the pharmacokinetic 
behaviour of the encapsulated compound. Thus, several 
studies have focused on tuning and comparing cannabinoid-
SEDDS and SNEDDS formulations. For example, medium 
and long chain triglycerides have recently been incorporated 
into SNEDDS in order to evaluate their effect on the oral 
absorption of major cannabinoids. Nevertheless, an investi-
gation in an in vivo preclinical model in healthy rats showed 
that these differences are masked after the incorporation of 
MCT and LCT into SNEDDS [147].
The lipids used in SNEDDS formulations may also have 
an impact on the pharmacokinetics of associated drugs, as in 
the case of CBD, which was orally administered to healthy 
rats in SNEDDS and compared to a formulation in sesame 
oil. The nano-formulation had a rapid onset of absorption 
but oily preparation was characterised with a prolonged 
absorption phase lasting 4–6 h [148]. The differences in the 
physicochemical properties (size, surfactants) of vehicles 
surely affected the cannabinoid solubilisation in gastroin-
testinal tract.
SNEDDS have also been compared to a CBD-contain-
ing floating gastro-retentive tablet that is based on an egg 
albumin matrix, gas-generating agents, and surfactants. 
Once administered to rats, the gastro-retentive dosage form 
showed a prolonged absorption phase with a substantial 
increase in bioavailability, compared to the CBD-lipid for-
mulation, thanks to gradual drug release. Indeed, dissolution 
into the aqueous environment of the stomach is a rate limit-
ing step for CBD, but when it occurs under sink conditions, 
the absorption is less dependent on this process [149].
To enhance the bioavailability of cannabinoids, the alka-
loid piperine has been combined with SNEDDS and orally 
administered to rats. The results showed an approximate 2.5-
fold increase in the oral bioavailability of CBD with piper-
ine dissolved in SNEDDS (once-daily dose) compared to 
CBD-SNEDDS alone. Nevertheless, there was no significant 
difference in CBD absorption with acute or chronic admin-
istration of piperine [150].
Other SEDDS formulations, in which antioxidants were 
added to the mixture, have been encapsulated in a gelatin 
or hydroxyl-propyl-methylcellulose capsule shell and orally 
administered to dogs. Cannabinoids in SEDDS achieved 
significantly higher oral bioavailability than the same 
dose administered orally in the form of an oil solution or 
a commercially available THC tablet. Nevertheless, when 
administered to evaluate the effects on the management of 
neuropathic pain, the cannabinoids in SEDDS achieved sig-
nificantly lower pain level scores than the same dose admin-
istered orally in the form of an oil solution [151].
Despite interesting results in animal models, reported 
cannabinoid pharmacokinetics have proven to be model-
dependent, and not uniform among research groups, and 
affected by the vehicle of administration. Thus, in order to 
investigate the oral absorption processes of CBD when given 
in oral formulations in healthy volunteers, CBD was admin-
istered in different formulations (powder form, dissolved in 
sesame oil and in SNEDDS) in a three-way, blind, cross-over 
single administration study on 12 subjects. The administra-
tion of CBD in both lipid-based vehicles resulted in a sig-
nificant increase in Cmax and AUC, compared to the powder 
form. Moreover, CBD in SNEDDS was rapidly absorbed in 
all volunteers, as opposed to the sesame oil group, which 
showed greater variability and less predictable pharmacoki-
netic behaviour [152]. These results again highlight the need 
for a standardised CBD oral formulation to reduce its high 
intra- and inter-subject absorption variability in humans.
A novel CBD-containing SEDDS formulation has been 
developed using food emulsifiers, edible vegetable oils and 
fatty acids, according to the  VESIsorb® technology, devel-
oped by Vesifact AG (Switzerland), which has previously 
increased the oral bioavailability of lipophilic molecules 
[153]. CBD has been used as a hemp-extract and SEEDS 
formulation, with the mean diameter of the droplets formed 
being between 40 to 50 nm and was compared to the same 
extract diluted with MCT oil. The authors evaluated the 
pharmacokinetic profile of SEDDS in a randomised, double-
blind, cross-over design in 16 healthy volunteers under fast-
ing conditions. A single oral administration of CBD-SEDDS 
led to an increase in both Cmax and AUC 0–8h/AUC 0–24h com-
pared to the reference formulation, while Tmax was shorter 
for SEDDS than for the MCT-form [129].
Nanotechnology formulations for cannabis-based extracts 
have been also proposed for oral and sublingual administra-
tions. Nanoemulsions, starting from oil droplets of prede-
termined sizes, have been prepared in the form of readily 
water-dispersible fine powders by lyophilisation. The dry 
fine lyophile powder is able to recover the oil droplets in 
approximately the same size, upon contact with water [154]. 
To reach this goal, the formulations should contain at least 
one cryoprotectant (such as sucrose, trehalose, or mannitol), 
at least one carbohydrate (such as maltodextrin and carboxy-
methyl cellulose) in great percentage and, in a proportion 
less than 5% at least one surfactant (such as ammonium 
glycyrrhizinate). The controlled combination of these com-
ponents allows tailored nanodroplets to be produced. From 
a technological point of view, an interesting comparison 
between microfluidic and ultrasound application to produce 
cannabinoid nanoemulsion has been recently proposed by 
Fathordoobady et al. [155, 156].
6.1.2  Minor Cannabinoids and Derivatives
Cannabichromene is a non-psychoactive, naturally occurring 
phytocannabinoid compound that is being selected by Can-
nabics Pharmaceuticals (USA) for the treatment of cancers, 
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including gastrointestinal cancer. Preclinical development 
is underway in Israel.
Cannabics Pharmaceuticals is also the proprietor of pat-
ents that describe a method of profiling the patient micro-
biome and cannabinoids [157], in order to select personal-
ised cannabinoid-based therapy for subjects diagnosed with 
cancer [158].
Regarding formulations proposed by Cannabics Pharma-
ceuticals, a supercritical  CO2 cannabinoid extract (that is 
then decarboxylated) (with 1.2–8% active substances) has 
been formulated with various amounts of mono and diglyc-
erides, coconut oil, lecithin and Iota carrageenan and admin-
istered in capsules. This approach has been proposed for 
the treatment of cachexia and anorexia in advanced cancer 
patients and their quality of life was monitored (n = 25) 
(NCT02359123). The trial concluded in 2018 [159].
Zyus Life sciences Inc. (CA) has been evaluating oral 
formulations comprising a mixture of THC, CBD and CBC, 
that are dispensed as pills, tablets or soft-gel capsules admin-
istered with high-fat food in amounts aimed at managing 
or treating pain in individuals. This study confirmed that 
CBC significantly prolongs the effect of CBD + THC in a 
preclinical rat model of neuropathic pain [160].
Synthetic derivatives of CBD have been developed by 
VivaCell Biotechnology (ES) and proposed for oral formu-
lations. One drug candidate, named EHP 101 (previously 
known as VCE-004.8, see Fig. 2) is a stable derivative of 
the CBD quinone (HU-331) and is administered as a liquid 
formulation. This candidate was proposed for the treatment 
of scleroderma and perhaps other fibrotic diseases [161, 
162]. Safety and tolerability clinical trials (NCT03745001, 
NCT04166552) are currently ongoing.
Another promising minor phytocannabinoid derivative, 
EHP 102 (previously known as VCE-003.2, see Fig. 2), 
which is derived from CBG, and its oral formulation are 
being developed by Emerald Health Pharmaceuticals (USA) 
(now called Skye Bioscience) for the treatment of Hunting-
ton’s disease and Parkinson’s disease. CBG is proposed as 
a cannabinoid with anti-inflammatory action, and there is 
some evidence of neuroprotection. This compound has been 
modified to be more effective than CBG as it can affect the 
peroxisome proliferator-activated receptor gamma (PPARγ), 
which is a key molecular target for the treatment of Hun-
tington’s disease, as well as being able to target other physi-
ologic pathways involved in neuronal survival [163, 164]. 
Preclinical development is underway in the USA where a 
lipid formulation of VCE-003.2 in corn oil is being used for 
oral administration [165, 166].
In addition to Sativex and Epidiolex, GW Pharmaceuticals 
is developing oral formulations of two minor cannabinoids, 
cannabidivarin (GWP42006) and Δ9-tetrahydrocannabivarin 
(GWP 42004). The former has been proposed for the treat-
ment of epilepsy, autism spectrum disorders, neuropathic 
pain and Prader-Willi syndrome. Clinical trials involve 
people with focal seizures (NCT02369471) and, more 
recently, children and young adults with autism spectrum 
disorder (NCT03849456). Tetrahydrocannabivarin-9 is an 
antagonist at the CB1 and CB2 receptors and may also act 
as a glucagon-like peptide-1 (GLP-1) secretagogue. An 
oral formulation of Δ9-THCV is in development for the 
treatment of type 2 diabetes mellitus. Clinical develop-
ment is underway in the UK and Romania (NCT02053272, 
EudraCT2013-001140-61) [167].
6.2  Oral Formulations for Colonic Delivery
Due to their important antioxidant and anti-inflammatory 
activity, cannabis and cannabinoids have also been pro-
posed for the treatment of inflammation processes of the 
intestine, although there is some debate over this use [168, 
169]. Cannabis use has been reported to be useful for the 
symptomatic control of inflammatory bowel disease, and has 
been reported as successful in the management of abdomi-
nal pain, joint pain, cramping, etc. Controlled-release forms 
are desirable in the attempt to limit the side effects, while 
significantly reducing the morbidity seen in patients with 
severe disease.
Furthermore, colon-specific drug-delivery systems can 
also be proposed for the treatment of a range of local dis-
eases, such as ulcerative colitis, Crohn’s disease, chronic 
pancreatitis, and colonic cancer. Very recently, some pat-
ents have appeared (by GW Pharmaceutics and ICD Pharma 
Ltd USA) proposing the use of cannabinoids in controlled-
release formulations to the intestine using a pH-dependent 
release polymer [170]. CBD, THC, and other cannabinoids 
can be loaded into microspheres, made of hydroxypropyl 
methyl cellulose acetate succinate, in the presence of a 
poloxamer emulsifier. Further, microspheres can be formu-
lated in suspension for enteric or colonic release, by means 
of modified cellulose or methacrylate copolymers (Eudragit 
S100).
Intestinal (small, large and colon) delivery formulations 
of cannabinoids have also been proposed by Friedman (ICD 
Pharma Ltd) [171]. Cannabinoids (CBD, THC, and cannabis 
extracts) were prepared as a hot melt dissolved in a mix-
ture of emulsifiers and solid-matrix-forming agents, such as 
polymers and waxes. When in contact with body fluids, the 
solid solutions eroded or swelled into tiny particles (below 
100 micron) improving the bioavailability of cannabinoids.
6.3  Pulmonary Administration
The most common route of administration for cannabis-
derived medicines is by inhalation, or smoking. The 
intrapulmonary administration of cannabinoids is regarded 
as an effective mode of delivery as it results in the fast onset 
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of action (5–10 min), rapid delivery to the central nervous 
system and high systemic bioavailability. Furthermore, this 
route of administration is useful for patients who are not in 
the condition to take oral medications (e.g., in the case of 
serious nausea and vomiting). To avoid the production of 
toxic by-products via combustion, vaporisation, which is a 
technique by which cannabis is heated to the temperature of 
cannabinoid vaporisation, but below the point of combus-
tion, has been proposed since the 1990s. Different types of 
vaporiser devices have been marketed; from larger desktop 
devices, such as the  Volcano® or the Arizer Extreme  Q®, to 
more portable models, such as the Arizer  Solo®,  Crafty® or 
 Mighty® Medic portable vaporisers (Storz-Bickel GmbH, 
same producer as the  Volcano®) or the Syqe Inhaler, devel-
oped by Syqe Medical (IL).
Regarding the evaluation of the analgesic effects of 
inhaled pharmaceutical-grade cannabis, van de Donk 
et al. have presented an experimental randomised study in 
chronic pain patients with fibromyalgia [172] (EudraCT 
2019-001861-33). The varieties used were Bedrocan (high 
THC/low CBD content), Bedrolite (high CBD/low THC 
content) and Bediol (high THC/high CBD content). All 
cannabis varieties were vaporised using the Volcano Medic 
vaporiser for intrapulmonary administration. The phar-
macokinetics and pharmacodynamics of three active can-
nabis varieties were described. It was observed that, when 
simultaneously inhaled, THC and CBD interact in complex 
fashions with synergistic pharmacokinetic, but antagonis-
tic, pharmacodynamic interactions. The analgesic efficacy of 
active treatment was limited to varieties that contained THC 
and was observed exclusively in the evoked pressure pain 
model. None of the active treatments were effective in reduc-
ing spontaneous pain scores more than the placebo. With 
inhaled forms of cannabis, the bioavailability is depend-
ent on the size of the vaping chamber, depth of inhalation, 
breath holding and the concentration of active components.
A combination of dry compressed cannabis standard-
ised in THC and CBD, plus several terpenes, for use as an 
inhalation product, is in Phase III development for the treat-
ment of pain and inflammation by Tetra Bio-Pharma (CA), 
while clinical development is underway in Canada and the 
USA (NCT04042545) [173]. The CAUMZ™ Kit comprises 
two coated capsules that mainly contain 17 mg THC and 5 
mg CBD (PPP001) in a PVC/aluminium blister pack, and 
a handheld  Mighty® Medic portable vaporiser. The drug 
component and device component can be assembled via the 
labelling of each component. The vapour to be inhaled is 
generated in a titanium pipe in the vaporiser via the heating 
of PPP001.
A Phase II trial in which inhaled PPP001 is evaluated 
against immediate-release oral opioids (morphine sulfate) 
for the management of breakthrough cancer pain is ongo-
ing in the USA (NCT03564548). Another Phase III trial is 
investigating patients with advanced cancer suffering from 
cachexia. Inhaled PPP001, in addition to palliative care man-
agement, will be assessed to ascertain whether these patients 
experience improvements in functional status, as a surrogate 
endpoint for survival, and quality of life (NCT04001010). 
An inhaled formulation of dronabinol, designated as 
HCC011, is also being proposed by Tetra Bio Pharma as an 
adjunctive treatment for hepatocellular carcinoma. Clinical 
development is underway in Canada.
Different from the vaporisation of cannabis fumes, an 
inhaled dry powder formulation of dronabinol is being 
developed by MannKind Corp. (USA) and Receptor Life 
Sciences (USA) and is based on the  Technosphere® platform 
[174–176]. This technology is centered on Technosphere 
particles, which are formed by the self-assembly of crystals 
of a proprietary excipient 3,6-bis(N-fumaryl-4-aminobutyl)-
2,5-diketopiperazine (FDKP). Cannabis extracts (mainly 
dronabinol) dissolved in ethanol in the presence of phos-
pholipids and other excipients were spray-dried with FDKP 
microcrystallites obtaining formulations containing up to 
30% of the cannabinoid. Clinical indications are for the 
treatment of chemotherapy-induced nausea, vomiting and 
anorexia in patients with acquired immunodeficiency syn-
drome. The  Technosphere® platform is characterised by the 
ultra-rapid onset of action, simple inhalation, the avoidance 
of hepatic metabolism and improved bioavailability (this 
technology is applied to produce human insulin powder for 
inhalation,  Afrezza®). Early-stage clinical development for 
pain disorders is underway in the USA.
An inhaled formulation of CBD as a dry powder is also 
being developed by TFF Pharmaceuticals (USA) for the 
treatment of an undisclosed indication. The use of the Thin 
Film Freezing (TFF) platform [177], which is still in the 
research phase, yields 'Brittle Matrix Particles' that have 
low bulk density, high surface area and typically amorphous 
morphology, allowing the particles to supersaturate when in 
contact with lung tissue. Early research is underway in the 
USA [178, 179].
Molecular Infusions LLC (USA) has proposed a soft mist 
inhaler, with a formulation made up of cannabinoids in etha-
nol and glycerol solutions, to reduce pulmonary irritation 
[180].
6.4  Transmucosal Administration
Transmucosal drug administration indicates the absorption 
of a drug through the mucosal epithelium into systemic cir-
culation. Intranasal, oral transmucosal and rectal routes are 
the major transmucosal routes that are used as alternatives 
to oral and parenteral administration.
A recent important review has thoroughly summarised 
the importance and limits of the transmucosal routes of 
drug administration in palliative care medication in order to 
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provide suggestions to give the best possible care to patients 
at the end of life during the COVID-19 pandemic [181].
Oral transmucosal delivery is based on the direct uptake 
of the drug by the highly vascularised oral mucosa. Dif-
ferent pharmaceutical dosage forms have been developed, 
including orally disintegrating tablets, buccal mucoadhesive 
tablets, films and patches, sublingual disintegrating thin 
films, sprays, chewing gum and lozenges. Upon administra-
tion into the oral cavity, the formulation dissolves in a small 
amount of saliva and the released drug diffuses across the 
epithelial barrier, reaching systemic circulation and avoiding 
first-pass liver metabolism. Furthermore, better compliance 
and acceptance are expected, particularly for paediatric and 
geriatric patients, who often experience trouble in swal-
lowing conventional tablets. One of the major challenges 
of buccal delivery is retaining the drug in the limited space 
in the mucosal oral cavity to achieve efficient partitioning. 
Furthermore, drugs can be unpalatable, bitter and can cause 
irritation to the oral mucosa, possibly leading to voluntary 
expulsion or swallowing. Physicochemical properties, such 
as small size (less than 500 Da), BCS class I or II, logP 2–4 
and high solubility in saliva, together with high pharmaco-
logical potency (meaning low doses are needed) are associ-
ated with achieving higher bioavailability. It is a popular 
route for drug administration that is used in palliative care, 
and several buccal formulations of opioid analgesics are 
commercially available.
A THC buccal formulation is being developed by Intel-
Genx Technologies Corp (CA) and Tetra-Bio Pharma for 
the treatment of cancer pain, chemotherapy-induced nau-
sea, vomiting and anorexia and weight loss in people with 
AIDS. A rapid release, buccal tablet formulation of THC is 
being developed to provide immediate symptom relief and 
easier dose titration. The sublingual product is formulated 
using IntelGenx technology (AdVersa™), which is based on 
orally dissolving films that protect and solubilise the THC, 
thereby enhancing its stability and increasing its bioavail-
ability [182].
Although several commercial products that contain CBD 
in oil have been proposed for transmucosal delivery, very 
few data are available on medicinal products in the litera-
ture and in patents. An oral sublingual formulation of CBD 
(BRCX 014) is being developed by Leaf Vertical Inc., now 
Diverse Biotech Inc. (USA), for the treatment of various 
cancers. Preclinical development is ongoing in the USA. 
The extraction and purification of CBD (> 99%) and some 
preliminary clinical tests, where cancer patients were treated 
with the standard-of-care therapy plus BRCX014, have been 
disclosed in a patent [183].
Moving on from CBD, Nabiximols formulations for 
use as an oromucosal spray (trade name  Sativex® from 
GW Pharmaceuticals plc., UK) have been proposed for 
the treatment of different disorders. It has been launched 
in several countries for the treatment of muscle spasticity 
in patients with multiple sclerosis. In Canada, the product 
has been approved for the adjunctive treatment of cancer 
pain and neuropathic pain in adults with multiple scle-
rosis. Clinical development is underway for cancer pain, 
muscle spasticity, post-traumatic stress disorders and 
glioblastoma in multiple countries. In the USA, Nabixi-
mols has FDA investigational new drug (IND) status for 
the treatment of spasticity. So far, 97 clinical trials have 
been carried out and 19 are either currently recruiting or 
planned. Nabiximols has also been proposed for use as 
an adjunctive analgesic treatment in adult patients with 
advanced cancer, who have moderate-to-severe pain dur-
ing the highest tolerated dose of strong opioid therapy 
for persistent background pain [184]. Although not supe-
rior to placebo in terms of the primary efficacy endpoint, 
Nabiximols seems to provide multiple secondary end-
point benefits, particularly in patients with advanced can-
cer who receive a lower opioid dose, such as individuals 
with early intolerance to opioid therapy. Nevertheless, a 
recent systematic review and meta-analysis to identify ran-
domised controlled trials of Nabiximols for the treatment 
of cancer-related pain was more critical [185]. In the six 
studies evaluated, when the change in pain intensity was 
the primary outcome, there was no statistically significant 
difference between the treatment and the placebo groups. 
Moreover, significant adverse effects and dropouts have 
been reported. One of the common adverse events of the 
chronic use of Nabiximols is mouth ulcerations (due to the 
ethanol excipient). An accurate evaluation to define the 
predictors of Sativex discontinuation in spasticity in mul-
tiple sclerosis has recently been published [186]. Physical 
disability and cognitive impairment were described for 
patients at risk of Nabiximols discontinuation over long-
term follow-up. A Phase Ib trial of Nabiximols oromucosal 
spray and temozolomide in the treatment of patients with 
recurrent glioblastoma demonstrated acceptable safety and 
tolerability without drug-drug interaction (NCT01812603, 
NCT01812616) [187].
The proposed use of Nabiximols to treat chronic pain 
was recently reviewed by Uberall. Its analgesic efficacy was 
more apparent in placebo-controlled clinical trials of chronic 
neuropathic pain, and, in particular, those with multiple 
sclerosis-associated neuropathic pain, with some patients 
maintaining long-term (up to 2 years) benefits. A German 
Pain e-Registry analysis of patients with severe chronic pain 
treated in daily practice with self-administered Nabiximols 
showed the best results in the neuropathic pain subgroup, 
compared to the nociceptive or mixed pain subgroups [188]. 
When considering the well-being of patients with chronic 
pain and looking beyond pain phenomenology, the presence 
of anxiety and stress are important predictors of response to 
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treatment. Both symptoms are reported to be significantly 
improved during treatment with the oromucosal spray.
The prevailing absorption route of oromucosal sprays is 
an interesting debate that may be, to some extent, correlated 
with results in pain treatment. Itin et al. have given a critical 
evaluation and proposed that the prevalent phenomenon was 
via the oral route, after swallowing, instead of absorption 
through the oral mucosa [189].
When selecting only Nabiximols trials with pain indica-
tions (n = 38), international clinical trials databases indicate 
that two studies are ongoing and are still recruiting; one on 
hyperalgesia in patients with deep endometriosis (EudraCT 
2018-004378-92) and one involving patients with chronic 
kidney disease (EudraCT2019-002786-35). Regarding deep 
endometriosis pain, another Phase III study in the recruiting 
phase, is investigating the effects of sublingual CBD alone or 
in combination with norethindrone acetate (NCT04527003).
Another oro-buccal spray formulation of CBD and THC, 
which uses Medlab's patented medicine delivery system 
named NanoCelle™, is being developed by Aphria Inc 
(CA) and Medlab Clinical Ltd (AU), for the treatment of 
pain, including cancer pain. The technology enables sub-
micron-sized particles to be taken as an oral spray. Clinical 
development for the treatment of cancer pain is underway 
in Australia [190, 191]. The preliminary results of a clinical 
trial (n = 25) (ACTRN12617001480370) have very recently 
shown that treatment with a CBD:THC (1:1) buccal spray 
resulted in an overall improvement in pain scores, including 
a greater than 30% average reduction in pain severity for 
the patient subgroup with bone metastasis (n = 8). Medlab 
have reported the development of a formulation of CBD and 
THC, named NanaBidial™, for the treatment of chemother-
apy-induced nausea, vomiting and seizures.
Several oromucosal formulations (rapidly dissolving tab-
lets) are in development. Pure Green Lab (USA) is study-
ing rapidly dissolving sublingual tablets with cannabinoid 
combinations for the treatment of dysmenorrhea (measured 
by a pain scale score) in a Phase II study (NCT04091789). 
The formulation contains, as the active substances, 30 
mg of CBD, 1 mg THC, 97 mg palmitoylethanolamide 
(which exerts a variety of biological effects, some related 
to chronic inflammation and pain) and a 0.2 mg combina-
tion of myrcene, beta-caryophyllene, humulene, linalool and 
limonene. A recent paper proposed that palmitoylethanola-
mide has an interesting synergistic anti-nociceptive effect 
with cannabis extracts [192].
Pure Green Lab is also studying the use of sublingual 
dissolvable tablets, mainly containing CBD and THC (1:1), 
in a study on the pain associated with osteoarthritis of the 
knee (NCT04195269).
Ethicann Pharmaceuticals (CA) is developing a CBD/
THC formulation using Catalent’s well-known  Zydis® 
oromucosal disintegrating tablet technology. These tablets 
disintegrate in the mouth in a very short time span, i.e., 
20–30 s, and the therapeutic action of active agent origi-
nates upon contact with saliva. This tablet technology is 
reported to allow increased drug loads and better taste 
masking. It is a patented technology based on the princi-
ple of the freeze-drying process [193, 194]. The matrix 
is composed of polymers, such as gelatine, dextran, or 
alginates, that are able to form a glassy amorphous struc-
ture, plus saccharides and flocculating agents to prevent 
the sedimentation of water insoluble drugs. Permeation 
enhancers, such as surfactants, may also be added to opti-
mise the transmucosal delivery of cannabinoids.
Oral and buccal formulations of cannabinoids have 
also been reported by NordicCan (DK) in different pat-
ents. These formulations include compressed gums, chew-
able liquid tablets, lozenges and pouch powder [195–197]. 
Analogously, Columbia Care LLC (USA) has filed a num-
ber of patents related to the delivery of cannabinoids via 
different routes; from sublingual/buccal formulations (of 
cannabinoid extracts with medium chain triglycerides, 
ethanol and polysorbate 80 as surfactant) to oral, topical 
and inhalation administration [198–201].
As the rectal mucosa is highly vascularised, this route 
of administration is useful for rapid systemic drug absorp-
tion; fast onset of action and a significant improvement in 
the bioavailability compared to the oral route (20–40%) are 
observed [43]. Furthermore, suppositories are thought to 
be useful for the administration of cannabinoids in patient 
conditions that render swallowing impossible, and in con-
ditions in which rectal administration is required, such 
as in situations experienced by patients as they approach 
the ends of their lives. Although no recent article has 
described this administration route for cannabinoids, a 
series of patents cover this topic. Axim Biotechnology has 
described the preparation of suppositories that are made 
up of cannabinoids in the form of a cannabis oil that is 
previously ‘nano’ encapsulated in a hyaluronic-derivative 
lattice [202].
A transmucosal cannabinoid formulation, including a 
chitosan excipient for rectal or vaginal delivery, has been 
reported by Tanaka [203]. The proposed method includes 
shea butter to extract cannabinoids from cannabis biomass, 
lecithin as a surfactant and the bioadhesive polysaccharide 
chitosan. This latter increased mucous-membrane and cel-
lular permeability, while also increasing the adhesion of the 
product to the cavity mucous membranes.
Columbia Care LLC have also proposed suppositories 
made of a mouldable polymer that includes a mixture of 
PEG of various molecular weights (1450 and 4000 Da) and 
a concentration of 2% of cannabinoid extracts [204].
The intranasal route is particularly attractive for the 
management of acute pain and breakthrough pain in cancer 
patients [205, 206]. Extensive vascularisation of the nasal 
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mucosa facilitates the fast onset of action and non-invasive 
administration. Moreover, if the medication is in contact 
with the olfactory mucosa, it may bypass the blood-brain 
barrier and cross directly into the cerebrospinal fluid.
Bryson has described both semi-solid and liquid nasally 
administered cannabinoid compositions and a device to 
provide precise nasal administration. A range of different 
formulations (oils, emulsions, gels) were disclosed and a 
pharmacokinetic evaluation on a small group of healthy vol-
unteers was performed [133]. Furthermore, in recent years, 
a series of patents has reported the nasal administration of 
cannabinoids, and have disclosed formulations and devices 
for administration, e.g., metered dose pump delivery devices 
as a multidose dispenser [207–211].
Nanostructured lipid carriers (NLCs), are made from a 
blend of solid and liquid lipids, in which the partially crys-
tallised lipid particles, with mean radii ≤ 100 nm, are dis-
persed in an aqueous phase containing one or more emulsi-
fiers. NLCs provide an increase in the loading capacity of 
active agents in the nanoparticles and avoid leakage during 
storage. Although some works have described the potenti-
ality of this carrier strategy, only a few works, which have 
exploited the mucoadhesive properties for nasal delivery, 
have recently been found [52, 212]. Matarazzo et al. have 
described the preparation, characterisation and in  vivo 
nociceptive activity of NLCs loaded with CBD [52]. Three 
formulations were compared in vitro and in vivo: a CBD 
solution, CBD loaded in NLCs, and CBD loaded in NLC 
with the addition of an in-situ gelling polymer in the NLCs 
dispersion (Pluronic). This latter was proposed as a means to 
further increase the mucoadhesive properties. NLCs loaded 
with CBD were obtained using the hot microemulsion tech-
nique, which employed stearic acid, oleic acid and sorbi-
tan monolaurate, while positively charged cetylpyridinium 
chloride was added to improve the bio-adhesiveness surface 
properties. The release studies showed that NLCs formula-
tions exhibited a burst effect, releasing about 50% of their 
CBD within 5 min. The in vivo evaluation in paclitaxel neu-
ropathic induced pain showed that intranasally administered 
CBD-NLCs dispersion produced a more significant and last-
ing antinociceptive effect than the nasal administration of 
CBD, both as a solution and as an NLCs dispersed in the gel.
6.5  Dermal and Transdermal Route
Drug administration through the skin is facilitated by its easy 
accessibility. Dermal formulations can be divided into trans-
dermal (for systemic effects) and topical (for local effects 
in the skin). From a physicochemical point of view, the 
requirements (recommendations) for transdermally admin-
istered drugs are: high potency (less than 10 mg/day), small 
molecular weight (less than 500 g/mol), moderate lipophi-
licity (logP 1–5) and a melting point of less than 250 °C. 
To improve skin-layer permeability, compound “permeation 
enhancers” can be frequently added, although skin irritation 
is often produced [213].
More recently, procedures that are based on micronee-
dles, thermal ablation and microderma abrasion have been 
investigated in human clinical trials to improve drug pen-
etration and to also deliver macromolecules, therapeutic 
proteins, and vaccines.
Transdermal patches have been proposed for both acute 
and chronic pain management. There are various systems 
available for the delivery of non-steroidal anti-inflammatory 
drugs, opioids, local anaesthetics, capsaicin, and nitroglyc-
erin. Patches are commonly used in paediatric practice.
Patches for the opioids fentanyl and buprenorphine are 
frequently used for symptom control and improvements to 
quality of life in patients with chronic pain related to osteo- 
or rheumatoid arthritis, in the palliation of malignant pain 
and in the other persistent pain syndromes [214, 215].
Regarding neuropathic pain, pathology and symptoms 
are restricted to a localised area of the body for about 60% 
of patients. Several studies have shown that patients with 
localised or peripheral neuropathic pain respond to analgesic 
treatment with peripheral agents. [216, 217].
Considering the physicochemical properties of cannabi-
noids, evidently high lipophilicity (logP around 6, against 
fentanyl at 3.9 and buprenorphine at 3.8) narrows skin per-
meability. Nevertheless, a skin reservoir effect has been 
observed for cannabinoids, and this is principally due to 
their highly lipophilic nature, which makes it easier for them 
to cross the stratum corneum but makes it difficult for them 
to traverse the aqueous dermis. Thus, synthetic approaches 
to produce prodrugs that are more skin permeable than the 
parent have been proposed by several companies. For an 
evaluation of the influence of vehicle-related aspects of CBD 
percutaneous absorption, the reader is directed to an article 
by Casiraghi et al. [218].
The case of Zynerba Pharmaceuticals Inc. (USA), who 
developed a synthetic d-glyceric acid ester pro-drug of THC 
administered as a transdermal patch (ZYN001 at 36 mg 
dose), is indicative of the complexities inherent in properly 
delivering cannabinoids through the skin [219]. Zynerba 
conducted Phase I development in the treatment of fibro-
myalgia and neuropathic pain in Australia. However, devel-
opment was subsequently discontinued (year 2018) because 
the study indicated that target blood levels of 5–15 ng/mL 
THC were not achieved.
An interesting nanotechnological approach is based on 
multi-layered lipid vesicles (MVLs), which were conceived 
to encapsulate THC for the topical and transdermal appli-
cations of cannabinoids in the treatment of pain. MVLs are 
formed by lipid bilayers that entrap both aqueous and oil 
phases in the form of a stabilised emulsion. Being lipophilic, 
cannabinoids are entrapped in the oil phase of the submicron 
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emulsion and may be further enclosed between the phos-
pholipid bilayers [220]. This formulation was proposed for 
transmucosal pain treatment by Altum Pharmaceuticals Inc 
(CA).
There is now increasing interest in transdermal appli-
cations of CBD. Preclinical data on the pharmacokinetics 
of CBD patches have been reported by Paudel et al. [221]. 
Transcutol-HP (diethylene glycol monoethyl ether), at 6% 
in a gel formulation, enhanced skin absorption 3.7-fold, 
in comparison with CBD in a propylene glycol-hydroxy-
ethyl cellulose gel [222]. Further approaches to improving 
cannabinoid transdermal penetration have been proposed 
by Stinchcomb et al. who first studied the in vitro human 
skin transdermal flux of α8-THC, CBN and CBD [223]. 
The same authors, from AllTranz Inc. (USA), now called 
Zynerba Pharmaceutics, have studied parent drug labile 
derivatives, CBD-esters and -carbonates among others, that 
can permeate the stratum corneum and, once they cross it, 
quickly separate back into the parent drug [224, 225].
Transdermal CBD, using an hydroalcoholic gel, for the 
reduction of inflammation and pain in a rat, induced mon-
oarthritis knee joint model was later studied [226]. This 
study confirmed that the transdermal administration of CBD 
may have a long-lasting therapeutic effect. A permeation-
enhanced CBD gel (Zygel™) for transdermal application 
then reached Phase II trials. Ethanol and propylene glycol 
were used as the solubilising agents, in addition to Transc-
utol-HP, which was used as the permeation enhancer. The 
alcohol content was about 54% (w/w), while the CBD con-
centration was 4.2% (w/w) in the final formulation. A recent 
patent claimed that this CBD gel could be used for the treat-
ment of focal epilepsy [227]. Heussler has reported that the 
gel was well tolerated and produced clinically meaningful 
reductions in anxiety and behavioural symptoms in children 
and adolescents with fragile X syndrome (n = 20), with an 
administration of 250 mg of CBD daily as a gel (n = 18, 
CBD administered up to 12 weeks) [228, 229], inducing a 
significant improvement in quality of life (NCT03614663). 
Clinical trials are still ongoing (ACTRN12618001063202 
and NCT03802799). Other applications of Zygel for the 
treatment of epilepsy, developmental and epileptic enceph-
alopathy, fragile-X syndrome, autism spectrum disorder 
(autistic disorders and pervasive child development dis-
orders), DiGeorge syndrome and osteoarthritis have been 
reported in recent patents [227, 230–232].
A topical CBD gel, designated CBD 100, is being devel-
oped by Futura Medical (UK) for the treatment of pain, and, 
potentially, other indications. The therapy is being developed 
with the  DermaSys® technology platform, which allows the 
rapid and targeted delivery of drug ingredients to be per-
formed at the required therapeutic levels. Preclinical devel-
opment is underway in UK.
Information on its web site indicates that Greene Street 
Pharma LLC (US) is developing a CBD transdermal patch 
for pain (still in research phase). The company is utilising 
its CBD-Cubed™ technology, which provides the sustained-
release (24-h delivery) transdermal delivery of CBD via a 
proprietary platform that combines adhesive and enhancer 
technologies. Transdermal patches have many advantages 
over alternative routes of administration and have been 
shown to improve patient adherence, as well as maintaining 
a steady concentration in the bloodstream. Early research is 
underway in the US, but no further information is available 
on the principal databases.
Synthetic versions of CBD are being used by Botanix 
Pharmaceuticals (AU), via their dermal/transdermal drug 
delivery technology, Permetrex™, for the treatment of skin 
disorders, including acne, plaque psoriasis, rosacea, atopic 
dermatitis and bacterial skin diseases [233]. Formulations 
include hexamethyldisiloxane, which acts as a volatile 
silicone carrier fluid and filming component, the lubricant 
polypropylene glycol and oleyl alcohol, with CBD being dis-
solved in isopropyl alcohol to reach a concentration ranging 
from 5 and 20%. Gel and spray formulations were proposed 
and clinical trials that investigated a topical occlusive system 
(BTX 1308) (ACTRN12618001802291) and a pump system 
(BTX 1503) (ACTRN12618001047280) were carried out. 
The exploration of novel silicone technologies in topical and 
transdermal drug delivery is quite important, as can be seen 
in the literature and filed patents [234, 235].
Topical cannabinoid delivery has been proposed for sev-
eral skin-related therapeutic conditions (in the treatment of 
psoriasis, atopic dermatitis and acne) and has recently been 
reviewed by Sheriff et al. [236]. A range of topical CBD 
products are currently being marketed in the USA, Europe, 
Canada and Australia under OTC regulations.
In particular, the benefits that CBD provided as an anti-
inflammatory agent in three patients affected by epidermoly-
sis bullosa have been described [237]. Paediatric patients 
benefited from the use of topical CBD (applied as an oil, 
cream, and spray by their parents) leading to a reduction in 
pain and blistering, as well as rapid wound healing.
Cannabinol has been observed to upregulate the expres-
sion of keratin 15, which improves skin integrity and reduces 
blister formation in patients with mutations of another ker-
atin (keratin 14). Furthermore, CBN, which preferentially 
binds to higher affinity CB2 receptor, can inhibit the produc-
tion of a variety of cytokines, and thus exhibit anti-inflam-
matory activity [238, 239].
A specific patent has also been filed by InMed Pharma-
ceutical Inc. (CA) [240], that described a cannabinol topical 
cream, designated INM-755, for the treatment of the symp-
toms of epidermolysis bullosa simplex, which is in develop-
ment. A randomised, Phase I trial that examined the safety 
and tolerability of two strengths of INM-755 cream on intact 
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skin in 22 healthy adult volunteers over a 14-day treatment 
period has recently been carried out (NCT04908215).
Cannabinoids are set to be clinically investigated for use 
in wound healing, although only anecdotal reports are cur-
rently available. Wound healing is an intricate process that 
includes overlapping inflammation, proliferation, and matu-
ration/tissue-remodelling phases. Maida et al. have described 
topical cannabis-based medicines, applied to both wound 
beds and peri-wound tissues, as promising non-invasive 
and safe treatment options for non-uremic calciphylaxis leg 
ulcers [241]. A base gel carrier of hyaluronic acid was used 
to topically administer a mixture of CBD and THC, supple-
mented with known active flavonoids, including quercetin, 
diosmin, hesperidin and beta caryophyllene, to wounds.
Clinically significant wound-related-pain relief has been 
provided by medical cannabis oils containing both THC 
and CBD in a small series of cases involving malignant 
wounds [242], and pyoderma gangrenosum [243]. In all of 
the above-reported cases, analgesia, with opioid sparing, 
and a trend towards wound healing were all demonstrated. 
It was affirmed that the effect of cannabinoids may be benefi-
cial in healing chronic wounds that are subject to prolonged 
inflammation.
It should be noted that One World cannabis (Subsidiary 
of OWC Pharmaceutical Research) completed a Phase I trial 
in healthy volunteers (NCT02976779) on the safety and 
tolerability of cannabis-extract-containing topical cream. 
A topical cream containing 3% (CBD:THC) has also been 
described for the treatment of psoriasis, and early-stage 
clinical development is underway in Israel [244].
6.6  Ophthalmic Delivery
There is an evident, growing body of literature on the oph-
thalmic impact of cannabinoids and, in particular, on its 
potential intraocular-pressure-lowering effects, the benefi-
cial effects on the retina, cornea and ocular motility. Current 
evidence on the effects of cannabis and related compounds 
on the disorders of the eye have recently been reviewed by 
Wang et al. [245]. The majority of clinical studies are related 
to cannabis consumption and ophthalmic effects, but pre-
clinical evaluations of topical administration and potential 
therapeutic uses are increasing in number.
Although cannabinoids have demonstrated ocular hypo-
tensive and neuroprotective properties, their use in treating 
glaucoma is limited by a significant number of potential side 
effects and by their limited solubility and penetration into 
ocular layers. Formulation studies and those on the synthesis 
of cannabinoid derivatives have flourished in recent years, 
although only preclinical evidence has been reported.
Improved formulations, based on cyclodextrins, topical 
solid lipid nanoparticles and fast gelling film formulations 
have also been reported. Some recent research on pain-treat-
ment results is discussed below.
A preclinical study has investigated the antinociceptive 
and anti-inflammatory effects of THC, CBD and derivative 
HU-308 using an experimental mouse model of corneal 
hyperalgesia that was generated by chemical cauterisation 
[246] (Fig. 2). The topical application of THC, CBD, and 
HU-308 [247], dissolved in soybean oil, either as sole agents 
or in combination, resulted in a significant reduction in pain 
scores [248]. Tetra Bio Pharma is developing HU-308, in 
Phase I, for dry eyes and uveitis and, as a parenteral formula-
tion, for the potential treatment of cytokine release syndrome 
and the potential prevention and treatment of SARS-COV-2 
acute respiratory disease.
An approach to help treat diabetic retinopathy-induced 
pain and inflammation using the anti-inflammatory proper-
ties of CBD has been described by Taskar et al. In order 
to produce a therapeutic effect, the molecule has to trans-
verse the static ocular layers and the dynamic blood-ocular 
barriers to reach the back of the eye. CBD analogues with 
amino-acid and dicarboxylic-acid ligands were synthesised 
to improve solubility. Figure 2 reports mono-substituted 
valine hemi-succinate, which significantly enhanced ocu-
lar bioavailability after topical application, compared to the 
other studied derivatives. All of the analogues were formu-
lated into a soybean oil-based emulsion using block copoly-
mer Pluronic F68 (Tocrisolve) as the emulsifier; a preclinical 
evaluation on rabbits was also reported [249].
InMed Pharma Inc. (USA) is actively working on can-
nabinoid eye delivery. For example, a hydrogel composite of 
the biocompatible and highly mucoadhesive polymers hya-
luronic acid and methyl-cellulose has been used to deliver 
cannabigerolic acid. In order to achieve sustained release for 
a prolonged duration, the drug was loaded into nanoparticles 
(composed of poly(ethylene oxide) and polylactic acid). An 
increase in in vitro corneal permeation of 300%, over control 
formulations, was observed [250, 251]. Moreover, advanced 
formulations, made up of stimulus-responsive nanoparticle 
gels, for glaucoma treatment have also been proposed [252].
Solid lipid nanoparticles (SLNs) are submicron particles 
made from solid lipids that have the potential to deliver 
hydrophobic compounds, such as cannabinoids, in differ-
ent treatment settings. SLNs have proven themselves to be 
suitable carriers for lipophilic substances and overcome hur-
dles in treating the eye posterior segment [253]. Accord-
ing to this approach, SLNs of THC–valine-hemi-succinate 
(THC–VHS) (a hydrophilic prodrug of THC with a better 
permeation profile than THC) were investigated, along with 
a nanoemulsion of THC–VHS, as a means to lower intraocu-
lar pressure in normotensive rabbits.
SLNs have been prepared using glyceryl behenate as the 
lipid phase, while the aqueous phase comprised polyoxyeth-
ylene-polyoxypropylene block copolymer (Pluronic F-68) 
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and polysorbate 80 as surfactants, plus glycerin. The interest 
in SLNs lies in their ability to prolong the residence time 
of the formulation in the cul de sac, thus acting as a drug 
reservoir and enhancing ocular bioavailability. Results have 
showed that THC–VHSSLNs, with multiple dosing, were 
able to achieve an intense and long-lasting intraocular pres-
sure drop, compared to the nanoemulsion formulation [254].
SLN can be also cited as a co-encapsulation approach, 
using dexanabinol (a synthetic cannabinoid derivative with 
neuroprotective effects) and curcumin (exhibiting antide-
pressant effects in the treatment of major depressive disor-
der) to evaluate the antidepressant effects in a mouse model. 
The study revealed that, although SLNs are able to overcome 
instability and the poor absorption of the loaded molecules, 
they had no antidepressant effects on the  CBR1–/– mouse 
models of major depressive disorder [255].
6.7  Less‑Explored Delivery Routes for Cannabinoids 
and Other Preliminary Studies
Because the parenteral administration of cannabinoids is not 
a common route, formulation studies are rare. Nevertheless, 
two recent studies on human subjects can be cited. The first 
is related to the characterisation of the pharmacokinetics of 
THC and its major metabolites in healthy volunteers, with 
known CYP2C9 status, using non-compartmental analy-
ses, compartmental modelling and minimal physiologically 
based pharmacokinetic modelling and was performed by 
Wolowich et al. [256].
Another recent exploratory, randomised, double-blind, 
placebo-controlled, cross-over study tested the effects of 
the IV administration of THC on pain response using a 
variety of human experimental pain models (intradermal 
capsaicin, mechanical, electrical, heat and cold procedures) 
[257] (NCT01595620). The conclusions of this investiga-
tion reveal that THC lacks antinociceptive effects in several 
forms of experimentally induced acute pain. The authors 
concluded that additional factors, such as pain paradigm, 
mode of drug administration, timing and other constituents 
of cannabis may be relevant and worth exploring. At the 
same time, there is a need for larger, high-quality, controlled 
studies to answer the growing demand for clinical applica-
tions of cannabinoids for pain management.
Nutrae LLC (USA) has filed three patents on the micellar 
encapsulation of cannabinoids for different administration 
routes (oral, IV, or inhalations and transdermal) [258–260].
Of the wide range of patents filed by GW Pharmaceutics, 
two report non-oily formulations for parenteral administra-
tion [261, 262]. The surfactant that is able to improve the 
solubility of CBD, in order to reach a water injectable solu-
tion 3–5 mg/mL, was macrogol 15-hydroxystearate (e.g., 
Solutol HS15), while glycerol and glucose appeared to be 
the best isotonic agents. Stability enhancers have also been 
added.
Several micro and nanotechnological applications to par-
enteral administration of cannabinoids are in development, 
although in preclinical trials. The most innovative examples 
are described below.
In an industrial project in development, Cardiol Thera-
peutics has developed a polymeric micellar formulation 
of CBD (CTX 01) for subcutaneous administration. This 
was designed to optimise and maintain blood levels of anti-
inflammatory and antifibrotic drugs and target their action to 
sites of inflammation and fibrosis for the treatment of heart 
failure. A CBD-loading value of 12% in micelles, with sizes 
of less than 100 nm, was obtained using a block copolymer 
with a structure consisting of methoxy poly(ethylene oxide)-
block-poly(α-benzyl carboxylate-ε-caprolactone). Pharma-
cokinetic evaluations in rats showed that micellar CBD (with 
4% CBD loading), subcutaneously administered, led to a 
greater amount of drug entering the bloodstream over 72 
h than free CBD solubilised in PEG 300 administered by 
same route [263]. The micelles seemed to preferentially 
and passively, localise in fibrotic tissue when administered 
systemically or subcutaneously, and more preferentially in 
association with cardiac fibroblasts.
Another nanotechnology formulation that is based on 
polymer loading CBD has been proposed by the Aphios 
Corporation (USA) as a product (compounds APH-1501 
and APH-1403). CBD was encapsulated into Poly Lactic-
co-Glycolic Acid (PLGA) polymer nanospheres using a 
superfluid stream of  CO2 and ethanol co-solvent, and then 
decompressed into a 1% polyvinyl alcohol buffered solution 
[264].
Another patented approach for the formulation of can-
nabinoid forms that are suitable for ingestion and topical 
application makes use of a cannabinoid-containing micellar 
aqueous solution of poloxamer and tocopherol-like com-
pounds. The cannabinoids are thus stabilised against oxida-
tion and/or photochemical degradation (SolMic Research 
GmbH, DE) [265].
Melt-printed polymeric micro-depots for full-spectrum 
CBD-rich extract administration have been proposed as 
long-acting formulations to release the whole-plant cannabis 
extract instead of its individual components. The formula-
tion consisted of polycaprolactone microspheres that were 
able to significantly extend the circulation time of multi-
ple phytocannabinoids, which have been suggested to have 
superior therapeutic effects compared to individual compo-
nents. Moreover, the long-term anticonvulsive activity of 
the micro-depots was observed after subcutaneous admin-
istration in a pentylenetetrazol-induced convulsion mouse 
model [266].
Lipid nanocapsules (LNCs) are biocompatible and bio-
degradable carriers that contain an inner oily core and are 
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prepared using a solvent-free and up-scalable process that 
is based on the energy-efficient phase inversion temperature 
method [267]. LNCs may be a suitable brain drug-delivery 
vehicle, while surface modification can further improve bio-
availability towards the central nervous system. For exam-
ple, LNCs have been loaded with CBD using a mixture of 
caprylic-capric acid triglycerides, as the oily vehicle, and 
poly-oxyethylated 12-hydroxystearic acid and soybean leci-
thin as the surfactants. The choice of the oily phase was 
based on the solubility of CBD, which can lead to a CBD/
oil (w/w) loading of 15%. The comparison between two dif-
ferently sized LNCs (20- and 50-nm) showed that the  IC50 
value was lower for smaller LNCs, as a consequence of the 
modified CBD release [268]. Furthermore, the surface func-
tionalisation of LNCs with CBD allowed the cannabinoid 
receptors overexpressed in glioma cells to be targeted, as 
demonstrated in permeability experiments across an in vitro 
blood-brain barrier model and in biodistribution experiments 
in mice [269]. Finally, the combination of CBD-loading and 
CBD-targeting has been observed to further reduce the  IC50 
values in glioma cells [268].
Other application of cannabinoids as potential anticancer 
agents regarded the use of micro and nanopolymeric parti-
cles for parenteral administration [270]. CBD was loaded 
into PLGA microparticles and compared to CBD in solu-
tion when administered in combination with either paclitaxel 
or doxorubicin for the evaluation of anticancer activity on 
breast cancer cells. Results showed that CBD-microparticles 
were effective as a monotherapy, showing extended anti-pro-
liferative activity, and also when combined with paclitaxel or 
doxorubicin. The anticancer efficacy of CBD-microparticles 
as a monotherapy and in combination with paclitaxel in tri-
ple negative breast tumours was also confirmed in the chick 
chorioallantoic membrane model [271].
Solid nanoparticles can be also produced applying a bot-
tom-up method based on antisolvent precipitation. This is a 
facile method with which to achieve the precipitation and 
stabilisation of nanoparticles of poorly water-soluble drugs 
[272]. CBD nanosuspensions have been prepared using this 
method with the addition of surfactants as stabilisers. In par-
ticular, different parameters were tuned in the formulation, 
such as the concentration of the mixture Span 80/Tween 
80 (1:4 w/w), CBD concentration and solvent/water ratio 
with ethanol as a solvent. The presence of surfactants stabi-
lised the mean dimensions of the formulations over several 
months of storage [273].
7  Discussion
The previous sections describe the efforts and interests of 
company research that has several different cannabinoids 
formulations in the pipeline, while numerous products are 
in advanced studies for a series of clinical needs. Table 3 
summarises ongoing clinical trials on the potential efficacy 
and clinical advantages of cannabinoids in the treatment of 
different pain conditions. The most frequent formulations 
are based on pure THC and standardised combinations of 
THC:CBD, while the preferred administration route is oral, 
followed by inhalation and transmucosal sublingual.
In parallel with the continuation of clinical evaluations, 
several systematic meta-analyses, reviews and novel clinical 
evaluations on the efficacy and safety of different cannabi-
noids in different formulations via different administration 
routes have very recently been reported.
Selecting studies focused on acute pain, Gazendam has 
analysed six oral administration trials, mainly, of THC. This 
analysis revealed that there was a small, but significant, 
reduction in subjective pain scores compared with placebo 
in patients experiencing acute pain [274].
More comparative evaluations have been reported for 
chronic non-cancer pain treatments.
Johal et al. have selected and evaluated 36 trials and 
found that cannabinoids are an effective form of pain control 
in this patient population, with a particularly strong effect 
for cannabinoids, mainly THC, that are orally administered, 
rather than oromucosally administered or smoked. There 
was moderate-quality evidence for cannabinoids having a 
small effect in treating chronic, non-cancer-related pain at 
all time points studied, up to 6 months. Moreover, small 
effects in pain reduction were found in patients with neuro-
pathic pain related to multiple sclerosis [275]. Furthermore, 
another recent evaluation demonstrated that Bedrocan with 
22% THC, administered with the Syqe Inhaler to 27 patients 
with neuropathic pain/complex-regional pain syndrome, 
provided a statistically significant decline in pain intensity, 
measured fifteen minutes after the inhalation of 0.5 and 1.0 
mg THC doses, and beyond [276]. Although the NIC guid-
ance on cannabis-based medicinal products allows for their 
prescription when there is an unmet clinical need related 
to chronic pain, CBD, alone or combination with THC, is 
not suggested for administration unless part of clinical tri-
als [277].
Considering medical cannabis for the reduction of opioid 
dosage in the treatment of non-cancer chronic pain, nine 
studies have been performed in which cannabis was smoked 
at a very wide range of concentrations (1.5–2000 mg). The 
nine available studies suggested that cannabis was effective, 
as an adjunct to opioids, in reducing the dosage of opioids 
in study participants. However, the design of several stud-
ies provides a limited basis upon which to make a rational, 
evidence-based recommendation [278].
Barry and Chris have presented a retrospective cohort 
study, from 2014–2018, in British Columbia. The outcomes 
of interest included the use of opioid/non-opioid pharmaco-
therapy, the number/frequency of visits and the proportion 
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of patients able to reduce/discontinue opioid therapy. The 
non-opioid pharmacotherapy with the highest proportion of 
patients perceiving a benefit was nabilone at 78%, while the 
lowest proportion was with gabapentinoids at 52%. Seventy 
patients with different chronic non-cancer pain disorders on 
opioid therapy demonstrated that almost 90% were able to 
successfully taper their opioid use, with an approximate 60% 
mean dose reduction over 12 months [279].
The available body of literature suggests that medical 
cannabis may be effective for the treatment of various non-
cancer-related pain disorders.
Nabiximols has undergone larger and more robust clinical 
trials than other cannabis-based products or medication for 
use in pain [280]. Nevertheless, head-to-head trials compar-
ing the safety and efficacy of types of medical cannabis are 
still expected.
Indeed, Mohiuddin et al. have focused their systematic 
review on the quality of safety assessment and reporting 
in chronic non-cancer pain cannabinoid trials (n = 43). 
When assessing the specific adverse effects experienced by 
trial participants, there were numerous effects that could 
adversely impact quality of life and adherence to treatment. 
Across all intervention subtypes, the most frequent adverse 
effects included dizziness, headache, fatigue, drowsiness, 
nausea, dry mouth, muscular weakness, headache and 
euphoria [281]. The frequency of serious adverse effects 
was 19.1% in studies of dronabinol, 4.4% in studies of oral 
THC:CBD capsules, 3.3% in studies of Nabiximols and 0% 
in studies of smoked THC and nabilone.
A randomised, double-blind, placebo-controlled trial on 
treating fibromyalgia with cannabinoids has recently been 
presented by Chaves et al. [282]. Oil extracts of cannabis 
had 24 mg/mL THC and 0.5 mg/mL CBD, although the 
terpenoid profile was not analysed, were administered sub-
lingually to 18 patients. The mean dose used in this study 
was 3.6 drops a day (4.4 mg of THC and 0.08 mg of CBD). 
At each visit, patients filled out a validated self-administered 
test that evaluated physical function, work status, well-being 
and associated physical and mental symptoms. Statistically 
significant improvements in the “feel good,” “do work,” 
and “pain” items in the cannabis group were found upon an 
analysis of the groups, and an additional improvement in the 
“fatigue” item was found in this same group, compared with 
the baseline value. However, the main cause of this benefit 
remains unclear.
A systematic review and meta-analysis on cancer-related 
pain management has identified few studies (six included) 
[185]. The Sativex oromucosal spray was administered ver-
sus placebo, and, in some studies, patients self-titrated to the 
optimal dose or were randomly assigned to different doses. 
Where change in pain intensity was the primary outcome, 
there was no difference between cannabinoids and placebo 
in the change in average numeric rating pain scale scores. 
An evaluation of the six randomised, double-blind, placebo-
controlled clinical trials where Nabiximols was administered 
for the treatment of pain in patients with cancer has shown 
that the differences in the studies may be caused by the vary-
ing study designs. However, the dosing of Nabiximols also 
varied among the studies. Some of the studies allowed self-
titration, whereas others provided a specific dose and dos-
ing interval. At this time, data supporting the effectiveness 
of cannabis and cannabinoids in the treatment of cancer-
related pain are limited. The conclusion of the authors is 
that Nabiximols may be an effective addition to cancer pain 
treatment in those who are not optimised on opioid therapy, 
but that effectiveness varies widely from one patient to the 
next. Thus, it may be proposed as being more beneficial as 
an adjunct to the standard-of-care treatment rather than as a 
replacement [283]. Moreover, Hauser has analyzed five stud-
ies and affirmed that there was no evidence-based argument 
to prescribe the use of medical cannabis or nabilone in can-
cer patients, but it was confirmed that more patients reported 
pain relief of 30% or greater in the Nabiximols arm than 
in the THC arm (23%) [284]. Nevertheless, cannabinoids 
have been also proposed for treatment of neuropathic pain 
induced by chemotherapeutics such as platinum derivatives 
or taxanes [285, 286]. This pain can be intense and poorly 
controlled by the use of opioids and the administration of 
THC in these patients, in addition to current pain therapy, 
may reduce the required dose of opioid, inducing a sense 
of well-being, thus counteracting the depression often pre-
sent in the cancer patient. In addition, cannabinoids could 
improve the quality of sleep, having an anxiolytic effect.
There have been a number of studies that have focused not 
only on pain, but also on HRQoL. A recent study provided 
12 months’ follow-up and has shown how the long-term 
use of cannabis can reduce pain intensity and pain-related 
interference scores. Moreover, HRQoL and general health-
symptom scores were improved compared with baseline, 
above all in men. Furthermore, the authors pointed out that 
patients, and even physicians, preferred cannabis in the form 
of oil. The favourable response to oil-based cannabis may be 
due to the slower onset of the effect compared with smok-
ing cannabis, as well as easier dose titration. Despite this 
interesting result, the authors highlighted that depression 
scores increased during the study [287]. Although the results 
are not conclusive, it is important to underline that further 
studies have shown that cannabis may have negative effects 
on the mental health of treated patients [288, 289], and that 
it may exacerbate neurological diseases such as epilepsy and 
anxiety [289].
It has also been highlighted that cannabis use has been 
associated with lower HRQoL in cancer patients. Neverthe-
less, patients would continue to use it, above all if severe 
symptoms are present. The effect of cannabis on cancer 
symptoms may be related to the amount of THC and its 
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ratio with CBD in the administered formulation, as well as 
to the dosage and method of intake [290].
Previous intake for medical or recreational purposes 
is a crucial aspect to consider when evaluating the effect 
of cannabis. This is in order to better understand the real 
perception of the effects in patients, who may be “naïve” 
or otherwise [291, 292].
Patients often report subjective benefits from cannabis 
for which there is no scientific evidence. It then becomes 
crucial to understand whether the subjective perceptions 
of cannabis benefits may be related to significant and per-
sistent changes in subjective well-being that may be sci-
entifically measurable.
Several studies have reported HRQoL evaluations for 
patients affected by pain and other pathologies that have 
been treated with cannabis, but, unfortunately, the major-
ity of these studies have limitations and cannot therefore 
be considered conclusive. First, the applied evaluation 
methods were not always uniform. In addition, the well-
being evaluation was often not a primary outcome, and 
the duration of the studies and sample sizes were highly 
variable [25]. Above all, the prescribed types of cannabis 
were different, both in terms of the variety, and therefore 
in the quantities of administered active molecules, and the 
route and time of administration. These aspects make the 
studies difficult to compare with each other [283].
The interesting results of a clinical audit on prescribed 
CBD oil have recently been described by Gulbransen et al. 
[293]. The study included 400 patients that were studied 
by Cannabis Care, New Zealand. The outcomes were 
defined using descriptive system measures of five domains 
(mobility, self-care, usual activities, pain or discomfort, 
anxiety, or depression), each with five levels of sever-
ity. The analgesic and anxiolytic benefits of CBD were 
observed in patients with non-cancer chronic pain and 
mental health conditions, such as anxiety. CBD was well 
tolerated, making it safe to trial for non-cancer chronic 
pain, mental health, neurological and cancer symptoms.
By analysing the administration route, cannabinoids 
used and formulations, a summative meta-analysis of can-
nabinoids for pain control has revealed that THC/CBD 
and THC, administered via the oromucosal route, repre-
sent the best score for neuropathic and cancer pains, while 
THC via the oral route had the best score for cancer pain, 
standardised dried cannabis via the inhalation route was 
best for neuropathic pain, and cannabis extract via the oral 
route was best for nociceptive pain. This suggests that pain 
reduction depends on the type of cannabis or cannabinoids 
used, the administration route and the type of pain [294]. 
CBD alone, via different routes and in different formula-
tions, seemed not to play a role in pain reduction. Never-
theless, a more recent preclinical study on different culti-
vars, which were extracted and well characterised, showed 
a similar analgesic effect both when the main component 
was THC and CBD, but, in this last case, the adverse effect 
(depression of respiratory rate) was not present [295].
The evidence for transdermal applications is increasing, 
and more effort to improve the efficacy and use of this route, 
which has shown ‘drug abuse’ potential, would be welcome. 
This route of adsorption has appeared to be relevant for sev-
eral companies in recent years, and, as an example, a CBD 
gel was well tolerated and produced clinically significant 
results in fragile X syndrome. This approach could be fur-
ther improved by exploiting the well-known microneedle 
system, in which biodegradable polymers deliver fluid mate-
rial by crossing biological barriers [296].
Among the oral formulations that stand out, we can find 
some novel approaches including Accordion Pills and co-
crystallisation, while the molecular conjugation approach 
(Kalytera) is more challenging. Moreover, cannabinoid 
formulations can take advantage of modern printing tech-
nologies, such as the fabrication of data-enriched edible 
pharmaceuticals (DEEP), which contain lipophilic cannabi-
noids (THC and CBD) that are inkjet-printed onto a porous 
substrate in the pattern of a QR code. These oral forms may 
allow the preparation of personalised doses and, at the same 
time, the incorporation of relevant data that are useful for 
the traceability of the drug product at a single dosage unit 
level. In this way, the strategy changes from “drug package 
labelling” into “in-drug labelling” [297].
Furthermore, transmucosal wafers have also been 
explored to improve the bioavailability of CBD [298]. 
Wafers are a simple drug carrier matrix with amorphous 
holes that can encapsulate oily CBD and facilitate sublin-
gual delivery. A very recent clinical trial was conducted in 
Australia and involved the sublingual administration of an 
oil and wafer drug-carrier matrix containing an oily solu-
tion with a high CBD content (Linnea 315CSE extract). The 
oily solutions and wafer were well tolerated and achieved 
increased CBD plasma concentrations compared to an avail-
able commercial Nabiximols formulation [299]. Transmu-
cosal Nabiximols have provided important results, and other 
formulations, such as tablets with mucoadhesive properties 
to avoid swallowing and increase absorption, have been con-
sidered as a means to improve performance.
Furthermore, this administration route has been explored 
for the development of promising delivery systems that also 
use nanotechnology approaches [300].
Despite the number of studies concerning micro- and 
nano-formulations, a comparison of efficacy in delivering 
cannabinoids remains difficult. Indeed, the literature reports 
experimental settings with different carriers, loaded mol-
ecules (pure active pharmaceutical ingredients or extracts) 
and in vitro/in vivo tests. Although interesting results in 
animal models have been described, the pharmacokinetics 
have proven to be model-dependent, not uniform among the 
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research groups, and affected by the vehicle of administra-
tion. Moreover, the intended target pathology is sometimes 
lacking in the papers. As an example, only one patent has 
reported an in vivo test on dogs to evaluate the management 
of neuropathic pain in the time period considered in this 
review [151]. Micro- and nano-formulation studies there-
fore appear to be very preliminary attempts to explore the 
possibility of exploiting nanotechnologies to deliver can-
nabinoids. From this point of view, lipid carriers seem to be 
the most suitable vehicle for lipophilic cannabinoids. Fur-
thermore, their production processes are scalable, although 
a complete physico-chemical characterisation has still to be 
carried out in order to standardise the described approaches.
Moreover, very few new nano-formulations are currently 
on the market or under clinical evaluation. This is probably 
because the most used cannabinoid-administration routes 
(i.e., oral and transmucosal) do not require the encapsulation 
of cannabis in nanosystems to prepare suitable formulations 
such as capsules or tablets.
8  Conclusion
In conclusion, the examples reported in the present review 
indicate that many remarkable formulations involving can-
nabinoids are now evolving and are being validated in sev-
eral clinical trials. Nevertheless, there is an urgent need for 
further research to investigate the optimal route and com-
position of cannabinoids in pain treatment, in large, high-
quality randomised clinical trials that can shed light onto 
the risks and benefits of cannabinoids in a controlled patient 
population. Multidisciplinary efforts, involving pharmaco-
logical and pharmaceutical technological sciences, have 
been joined by increased investment in research to help those 
who suffer, while not unintentionally causing hazardous con-
sequences. At the same time, the legal, ethical, and medical 
aspects of improving regulation will be crucial if high qual-
ity, high-safety cannabinoid medicines are to be produced.
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